Significance Statement {#s1}
======================

Temporally and spatially controlled genetic reversal of mouse models of autism are used to determine critical windows in development for successful treatment. This study provides a clear example that any attempt at genetic reversal must be accompanied by all appropriate controls, including expression of the *Cre^Tam^* transgene in wild-type (WT) animals, for accurate interpretation of the genetic rescue result. In addition, this study provides two additional independent replications of behavioral and synaptic electrophysiologal abnormalities in *Shank3* exon 21 mutant mouse models in the *Cre^Tam^*-negative cohorts. Reproducibility and rigor are important and sometimes overlooked aspects of many mutant mouse behavioral and electrophysiological studies.

Introduction {#s2}
============

*SHANK3* (*ProSAP2*) is one of the most common genes associated with ASD and is implicated in bipolar disorder, schizophrenia, and Alzheimer's disease (for review, see [@B9]; [@B10]). The *SHANK3* gene is located on the long arm of chromosome 22 at position 22q13.3 and is the causative gene in Phelan--McDermid syndrome (PMS; [@B4], [@B5]; [@B7]; [@B2]). The gene encodes SHANK3, a postsynaptic scaffolding protein that interacts directly or indirectly with AMPA receptors ([@B26]; [@B22]), NMDA receptors ([@B20]), metabotropic glutamate receptors ([@B28]), and the actin cytoskeleton ([@B18]; [@B20]; [@B23]; [@B3]) at excitatory synapses in the brain.

Human *SHANK3* mutations and changes in copy number have been modeled in mouse models (for review, see [@B15]). Our laboratory has characterized four independent mouse lines by targeting exons 4--9 ([@B13]), exon 13 ([@B14]), and exon 21 ([@B17]; [@B25]) of *Shank3*.

We have reported consistent biochemical, behavioral, and physiologic findings in two *Shank3* mouse models targeting the C-terminal domain of the SHANK3 protein (exon 21). One of these models was made by deletion of exon 21 (*Shank3^ΔC^*), loosely mimicking an autism-associated, human guanine insertion mutation that caused a frameshift mutation and premature STOP codon in exon 21 ([@B17]). We identified behavioral deficits in *Shank3^ΔC/ΔC^* mice, including novelty avoidance and motor coordination abnormalities ([@B17]). Synaptic transmission and synaptic plasticity were also decreased in *Shank3^ΔC/ΔC^* mice in area CA1 of the hippocampus ([@B17]).

More recently, we have mimicked this autism-associated *SHANK3* mutation by inserting a guanine nucleotide at position 3728 of *Shank3* to cause an equivalent frameshift mutation and premature STOP codon in exon 21 ([@B25]). This *Shank3^G^* mouse shared similar phenotypes with the *Shank3^ΔC^* mouse, including loss of SHANK3 protein isoforms, novelty avoidance, motor deficits, and deficits in synaptic transmission in area CA1 of the hippocampus ([@B25]). We engineered the *Shank3^G^* mutant model as a Cre-recombinase-dependent, genetically reversible model ([@B25]). In our original publication, we demonstrated that genetic reversal of the *Shank3^G^* mutation by Cre-recombinase restored SHANK3 protein to levels indistinguishable from wild-type (WT) *Shank3^+/+^* ([@B25]). The common phenotypes of *Shank3^G^* and *Shank3^ΔC^* mouse lines underscored the robust, reproducible nature of these findings for future studies.

In the present study, we sought to answer whether autism caused by *SHANK3* mutation is a "hard-wired," irreversible neurodevelopmental disorder or a disorder of brain function that can be reversed by normalizing *SHANK3* expression following completion of brain development. This question has important ramifications for both targeting and timing of potential therapeutic strategies. We hypothesized that adult-induced genetic reversal of *Shank3^G^* mutant mice would result in rescue of behavioral and electrophysiologic abnormalities in our genetically reversible *Shank3^G^* mutant model. This hypothesis has was examined using a similar genetic reversal strategy in other autism-related mouse models including *MeCP2* ([@B11]), *Ube3a* ([@B24]), *Syngap1* ([@B6]), and *Shank3* ([@B19]) mutants.

Our findings in Cre-negative mice replicated our previously published behavioral and synaptic abnormalities in the *Shank3^G^* mouse line, further underscoring the robust and reproducible nature of these findings. At first glance, our results in tamoxifen-treated, Cre-positive, genetically reversed mice appeared to demonstrate rescue of some, but not all, phenotypes. Our test of this hypothesis, however, included critical controls run in parallel with the key genetic reversal experiments that illuminated potential caveats to interpretation of genetic reversal experiments using the *Cre^Tam^* transgenic mouse line ([@B12]; [@B11]; [@B6]; [@B24]; [@B16]; [@B19]).

Materials and Methods {#s3}
=====================

Generation and genotyping of *Shank3^G/G^* mice with and without *Cre^Tam^* {#s3A}
---------------------------------------------------------------------------

Construction of the genetically reversible, *Shank3* exon 21 insertion mutant targeting vector and resulting genetically reversible *Shank3^G/G^* mouse line were described previously ([@B25]). Genotyping for *Shank3* was performed as described ([@B25]) with two primers: 21M-loxP1-sequence-sense (CTGTTGGTGTCAGTTCTTGCAGATG, in intron 20) and 21M-sequence-loxP2-antisense (CAAGGATGCTGGCCATTGAATGGCTTC, in exon 21). PCR products for WT *Shank3* and *Shank3^G^* alleles were 596 and 638 bp, respectively. Following Cre-recombination, the PCR product of the recombined *Shank3^G-Rev^* allele was 680 bp. Genotyping for the *Cre^Tam^* transgene was performed with two PCR primers: sense (GCGGTCTGGCAGTAAAAACTATC) and antisense (GTGAAACAGCATTGCTGTCACTT). PCR product for *Cre^Tam^*transgene gene was ∼100 bp.

Heterozygous mice from the original *Shank3^G^* mouse line ([@B25]) were crossed with a tamoxifen-inducible *CAGGCre-ER^TM^* transgenic mouse line driven by the chicken beta actin promoter/enhancer coupled with the cytomegalovirus (CMV) immediate-early enhancer from The Jackson Laboratory (strain: B6.Cg-Tg(Cre/Esr1\*)5Amc/J; [@B12]). We refer to this tamoxifen-inducible transgene as *Cre^Tam^* throughout. This cross yielded WT (*Shank3^+/+^*) and heterozygous (*Shank3^+/G^*) mutant mice with (*Cre^Tam^+*) and without (*Cre^Tam^−*) the *Cre^Tam^* transgene. Next, heterozygous *Shank3^+/G^*mice with the *Cre^Tam^* transgene (*Shank3^+/G^Cre^Tam^+*) were crossed with heterozygous *Shank3^+/G^*mice without the *Cre^Tam^* transgene (*Shank3^+/G^Cre^Tam^−*). This final cross yielded all experimental mice ([Figs. 1](#F1){ref-type="fig"}, [2](#F2){ref-type="fig"}).

![Breeding strategy for generating the *Shank3^G^Cre^Tam^* mouse line. Heterozygous *Shank3^+/G^* mice from the original *Shank3^G^* mouse line were crossed with a tamoxifen-inducible *Cre^Tam^* transgenic mouse line to produce *Shank3^+/G^Cre^Tam^−* and *Shank3^+/G^Cre^Tam^+* offspring. *Shank3^+/G^Cre^Tam^−* and *Shank3^+/G^Cre^Tam^+* mice from this initial cross were bred to generate all experimental mice for this study: *Shank3^+/+^Cre^Tam^−*, *Shank3^+/G^Cre^Tam^−*, *Shank3^G/G^Cre^Tam^−*, *Shank3^+/+^Cre^Tam^+*, *Shank3^+/G^Cre^Tam^+*, and *Shank3^G/G^Cre^Tam^+*.](enu9991930480001){#F1}

![Tamoxifen treatment strategy. Experimental mice of all six genotypes (*Shank3^+/+^Cre^Tam^−*, *Shank3^+/G^Cre^Tam^−*, *Shank3^G/G^Cre^Tam^−*, *Shank3^+/+^Cre^Tam^+*, *Shank3^+/G^Cre^Tam^+*, and *Shank3^G/G^Cre^Tam^+*) were fed vehicle diet until eight weeks of age. At eight weeks, mice were separated into two treatment groups, one receiving vehicle diet for six weeks and another receiving tamoxifen diet for six weeks. Each treatment group consisted of mice from all six genotypes. After the six-week treatment, all mice were fed vehicle diet for at least a two-week wash-out period before testing. During and after testing, all mice were fed vehicle diet.](enu9991930480002){#F2}

Sex-matched littermates of mixed *Shank3* and *Cre^Tam^* genotypes were housed together two to four per cage on weaning at postnatal days P21--P28. Mice were kept on a 12/12 h light/dark cycle with experiments performed during the light cycle (6 A.M. to 6 P.M.). Mice were allowed free access to food and water. Mice receiving tamoxifen treatment were housed in the same room, but on a separate rack from mice receiving vehicle.

In the *Shank3^G^Cre^Tam^+* mice, tamoxifen administration allowed Cre-recombinase to be transported into the nucleus to excise the mutated S*hank3* exon 21, resulting in WT SHANK3 expression and effectively reversing the mutation ([Fig. 3](#F3){ref-type="fig"}). The *Shank3^G^Cre^Tam^−* mice also were subjected to behavioral, biochemical, and electrophysiological testing to identify any unanticipated effects of the *Cre^Tam^* transgene or of tamoxifen administration.

![Tamoxifen-inducible *Shank3* genetic reversal strategy. The *Shank3^G^* mutation was introduced into the WT *Shank3* allele (***A***) by insertion of a neo-STOP cassette before WT exon 21 (***B***). The neo-STOP cassette was flanked by loxP sites, so that Cre-recombinase activity in the nucleus could excise the mutated S*hank3^G^* exon 21 (***C***), resulting in restoration of the WT *Shank3^+/+^* gene (***D***) and SHANK3 expression, thereby effectively reversing the *Shank3^G^* mutation.](enu9991930480003){#F3}

Biochemistry {#s3B}
------------

Western blottings were performed as previously described ([@B17]). To determine rescue of SHANK3 expression following tamoxifen treatment, SHANK3 protein levels were determined by immunoblotting whole-brain tissue homogenized in artificial CSF (ACSF), 5 mM EDTA, and 1× Halt protease and phosphatase inhibitor cocktail (Thermo Scientific); 10 μg of protein was loaded per lane and blotted with an anti-SHANK3 antibody (gift of Paul Worley) and anti-β-actin antibody was used as an internal loading control. An Image Works film processor was used to develop films and the chemiluminescent signals were quantified, normalized, and analyzed using Image Studio, Microsoft Excel, and Statistica software (Version 13, Dell Inc).

Tamoxifen administration {#s3C}
------------------------

The route and dose of tamoxifen administration were determined by comparing the SHANK3 protein levels in adult *Shank3^G^Cre^Tam^+* mice receiving 15-d subcutaneous injection of 4-hydroxytamoxifen or in mice being fed tamoxifen custom chow for one to four weeks ([Fig. 4](#F4){ref-type="fig"}). Daily injections of 4-hydroxytamoxifen (66.67 mg/kg, Sigma-T176, Sigma-Aldrich) stimulated a modest increase in expression of SHANK3 in *Shank3^+/G^Cre^Tam^+* and *Shank3^G/G^Cre^Tam^+* mice compared to *Shank3^+/+^Cre^Tam^+* controls ([Fig. 4*A*)](#F4){ref-type="fig"}.

![Optimization of tamoxifen treatment protocol in adult *Shank3^G^Cre^Tam^+* mice. ***A***, Quantification of Western blotting showing minimal rescue of WT SHANK3 protein expression following treatment with 4-hydroxytamoxifen (66.67 mg/kg) given once per day subcutaneously for 15 d (*n* = 7 for all treatment groups). ***B***, Representative Western blotting (top) and quantification of whole-brain lysates (bottom) showing degrees of rescue of SHANK3 protein expression after varying duration of tamoxifen diet (*n* = 7 for all treatment groups). ***C***, SHANK3 protein levels from whole-brain lysates in adult *Shank3^G^Cre^Tam^−* mice treated for six weeks with vehicle or tamoxifen diet (vehicle diet: *Shank3^+/+^ n* = 9, *Shank3^+/G^ n* = 7, *Shank3^G/G^ n* = 4; tamoxifen diet: *Shank3^+/+^ n* = 12, *Shank3^+/G^ n* = 9, *Shank3^G/G^ n* = 9). ***D***, SHANK3 protein levels from whole-brain lysates in adult *Shank3^G^Cre^Tam^+* mice treated for six weeks with vehicle diet or tamoxifen diet \[vehicle diet: *Shank3^+/+^ n* = 26, *Shank3^+/G^ n* = 21, *Shank3^G/G^ n* = 15; tamoxifen diet: *Shank3^+/+^ n* = 23, *Shank3^+/G^ n* = 15, *Shank3^G/G^ n* = 18; data are normalized to the β-actin control and then to the average of WT levels with C-terminal SHANK3 antibody (JH3025)\]. ***E***, Example Southern blotting of brain tissue in *Cre^Tam^*+, WT and *Shank3^G/G^* homozygous mutant mice treated with vehicle or tamoxifen (TAM; Rev = band expected following cre-mediated recombination of floxed mutant; Mut = band expected for floxed mutant before cre recombination; WT = band expected in WT mice without mutant allele); \**p* \< 0.05, \*\**p* \< 0.01, \*\*\**p* \< 0.001, \*\*\*\**p* \< 0.0001. Error bars represent S.E.M. in this and all subsequent figures.](enu9991930480004){#F4}

Oral treatment with tamoxifen diet (950 g/kg 16% Protein Rodent Diet, 500 mg/kg tamoxifen USP, 49.5 mg/kg sucrose, catalog \#TD.130857, Envigo) provided a dose of ∼80 mg/kg/d for a 20- to 25-g mouse. Beginning at eight weeks of age, *Cre^Tam^+* and *Cre^Tam^−* mice were randomly assigned to the vehicle diet group or the tamoxifen diet group and fed *ad libitum* for one, two, or four weeks followed by a two-week washout period.

Rescue of SHANK3 expression in *Shank3^+/G^Cre^Tam^+* and *Shank3^G/G^Cre^Tam^+* mice with tamoxifen diet increased with duration of treatment from one to four weeks ([Fig. 4*B*)](#F4){ref-type="fig"}. In our final experimental design, we used a six-week treatment with tamoxifen diet to further ensure complete reversal. In the final analysis, six weeks of tamoxifen diet proved most effective in rescuing SHANK3 protein levels in *Shank3^G^Cre^Tam^+* mice ([Fig. 2*C*,*D*](#F2){ref-type="fig"}). Thus, for the actual experiments, mice in the both groups were fed 16% Protein Rodent Diet (vehicle, Envigo) until eight weeks of age, and then the tamoxifen-treated group were fed tamoxifen chow for six weeks. Tamoxifen-treated mice were returned to their original vehicle diet for at least a two-week washout period before the start of all experiments. Mice in the control group were maintained on vehicle diet throughout the treatment and wash-out periods. Food intake and body weight were unchanged during tamoxifen administration (data not shown).

Behavioral overview {#s3D}
-------------------

Behavioral tests were performed during the light cycle on four cohorts: two cohorts with cre-recombinase (*Shank3^G^Cre^Tam^+*) ± tamoxifen treatment and two cohorts without cre-recombinase (*Shank3^G^Cre^Tam^****−***) ± tamoxifen treatment. All cohorts consisted of age- and sex-matched littermate progeny of heterozygous matings ([Fig. 1](#F1){ref-type="fig"}). The appearance of unequal N's was due to some littermate triplets (WT/het/homo) and some littermate pairs (WT/het or WT/homo) being used, with each heterozygous or homozygous mouse having at least one sex-matched littermate WT in the cohort.

All mice in each cohort were born within 12 weeks of each other. Tamoxifen dosing for the behavioral cohorts began when each pair or triplet was eight weeks of age. Tamoxifen treatment continued for six weeks before resuming a regular diet. Behavioral testing began when the mice were four to six months of age by an experimenter blind to genotype in the following order: locomotor, marble burying, rotarod, and nesting behavior. Behavioral results are not described in the order in which they were tested to simplify presentation of the data. One *Shank3^+/G^Cre^Tam^+* mouse treated with tamoxifen was found dead in its cage before marble burying behavior, so its littermate-paired, WT *Shank3^+/+^Cre^Tam^+* mouse treated with tamoxifen was excluded from the future experiments.

Locomotor {#s3E}
---------

Locomotor activity was tested by placing the mice in a fresh home cage with minimal bedding. Their activity was monitored for 2 h using photobeams linked to a computer with data acquisition software (San Diego Instruments; [@B21]) in the dark. Three-way repeated measures ANOVA (rmANOVA) was used to analyze the data with genotype and sex as between-subject factors and time as a within-subject factor.

Marble burying {#s3F}
--------------

As previously described ([@B1]), twenty marbles were evenly placed around a novel home cage with 5 cm of bedding and mice were given 30 min in the cage. After 30 min, the number of marbles buried was recorded. A marble was defined as buried when \<25% of the marble was visible. The test room was well lit (∼80 lux). Data were analyzed using two-way ANOVA with genotype and sex as between-subject factors.

Accelerating rotarod {#s3G}
--------------------

Coordination and motor learning were tested using a rotarod as previously described ([@B21]). In a well-lit room (∼80 lux), mice were placed on a stationary rotarod (IITC Life Sciences) that was then activated and accelerated from 0 to 45 revolutions over 5 min. The latency for mice to fall off the rod or take one revolution was measured. Trials were repeated four times per day with intertrial intervals of 30 min for 2 d. Data were analyzed using three-way rmANOVA with genotype and sex as between-subject factors and trials as a within-subject factor.

Nesting {#s3H}
-------

Nesting behavior was performed in a well-lit (∼80 lux) room by first habituating the mouse to a novel, clean home-cage with ∼1.5 cm of bedding for 15 min. Then a cotton nestlet (5.5 × 5.5 × 0.5 cm) was put in the cage. Height and width of nests were measured at 30, 60, and 90 min ([@B8]). Data were analyzed using three-way ANOVA with genotype and sex as between-subject factors and time as a within-subject factor.

Acute slice preparation {#s3I}
-----------------------

Acute slice preparation was performed as previously described ([@B25]) with minor modifications. Sixteen-week-old male mice from both the vehicle and tamoxifen treatment groups (*Shank3^+/+^Cre^Tam^+*, *Shank3^+/+^Cre^Tam^−*, *Shank3^G/G^Cre^Tam^+*, and *Shank3^G/G^Cre^Tam^−*) were administered a lethal dose of 8% chloral hydrate (≥400 mg/kg) and perfused through the heart with ACSF. The brains were rapidly removed and cut 350--400 μm thick in ice-cold, modified dissecting ACSF on a vibrating microtome (Vibratome 3000, Leica Biosystems). Coronal slices containing hippocampus were brought to 35 ± 0.5°C for 30 min and allowed to slowly cool to room temperature, where they remained until recording at 32°C.

Extracellular "field" electrophysiology {#s3J}
---------------------------------------

Field EPSPs (fEPSPs) were generated by a 100-μs biphasic pulse through a monopolar nickel dichromate stimulating electrode as previously described ([@B25]). The stimulating and glass recording electrodes (1--2 MΩ) were placed laterally in the stratum radiatum 400--500 μm apart. Data were collected using Model 2100 stimulus isolators and Model 1800 amplifiers (A-M Systems) at 10 kHz sample rate with a 1- to 5-kHz high-pass filter. Data were acquired and analyzed using the pClamp software suite (v 10.3, Molecular Devices), Prism (v 6.0, GraphPad), and Statistica (v 13, Dell Inc).

After a stable 20-min baseline was achieved at 0.05 Hz, input/output (I/O) curves were measured over a range of stimulus intensities (0--350 μA) in 50-μA increments at 0.05 Hz. The maximum slope (10--90%) of the fEPSP was analyzed at eight different stimulus intensities with five repetitions at each stimulus intensity. All recordings were performed at 32°C with an average of two to three slices per mouse. Data were analyzed using two-way rmANOVA with genotype the between-subject factor and stimulus intensity as a within-subject factor.

Solutions {#s3K}
---------

ACSF contained the following: 120 mM NaCl, 3.5 mM KCl, 1.25 mM NaH~2~PO~4~, 1 mM MgSO~4~, 26 mM NaHCO~3~, 10 mM dextrose, and 2 mM CaCl~2~. Dissection ACSF consisted of the following: 75 mM sucrose, 87 mM NaCl, 3 mM KCl, 1.25 mM NaH~2~PO~4~, 7 mM MgSO~4~, 26 mM NaHCO~3~, 20 mM dextrose, and 0.5 mM CaCl~2~. All solutions were adjusted to pH 7.4 and saturated with 95% O~2~/5% CO~2~.

Statistics {#s3L}
----------

Plotting was performed with OriginPro 2016 (OriginLab Corporation). All statistics were performed in Statistica (v 13, Dell Inc). Significance was determined at the *p* \< 0.05 level. A main effect of genotype or sex was followed by a Tukey HSD test to determine significance of each group compared to control. For detailed numerical statistical results see [Tables 1](#T1){ref-type="table"}, [2](#T2){ref-type="table"}.

###### 

Detailed statistical analysis of tamoxifen treatment on WT SHANK3 protein expression

  Biochemistry                                                                                                                                                                                                                                                                                                                                                                                                                                                             
  -------------------------------------- --------------- -------------------------------------------------------------------------------------------------------------------------------------------------------------------------------- ------------------------------------------------------------------------------------------------------------------------------------------------------------------- ------------------------------------------------------------ ----------------------------------------------------------------------------------------------------------------------------
  15-dTAM s.c. vsVeh s.c. (Cre+)         Two-way ANOVA   GenotypeTreatmentInteraction                                                                                                                                                                                                                                                                                                                         *F*~(2,36)~ = 20.97*F*~(1,36)~ = 1.61*F*~(2,36)~ = 0.49      *\*p* \< 0.0001*p* = 0.2133*p* = 0.6194
  ([Fig. 4*A*](#F4){ref-type="fig"})     Tukey HSD       Veh *Shank3^+/+^* vsVeh *Shank3^+/+^*vs Veh *Shank3^+/G^* vsVeh *Shank3^+/+^*vsVeh *Shank3^+/+^*vsVeh *Shank3^+/+^*vsTam *Shank3^+/+^*vsTam *Shank3^+/+^*vsTam *Shank3^+/G^*vs   Veh *Shank3^+/G^* Veh *Shank3^G/G^* Veh *Shank3^G/G^* Tam *Shank3^+/+^* Tam *Shank3^+/G^* Tam *Shank3^G/G^* Tam *Shank3^+/G^* Tam *Shank3^G/G^* Tam *Shank3^G/G^*                                                                *p* = 0.0705*\*p* = 0.0003*p* = 0.2997*p* = 1.0000*p* = 0.6835*\*p* = 0.0024*p* = 0.6835*\*p* = 0.0241*p* = 0.0998
  One-weekTAM diet vs Veh diet (Cre+)    Two-way ANOVA   GenotypeTreatmentInteraction                                                                                                                                                                                                                                                                                                                         *F*~(2,36)~ = 25.49*F*~(1,36)~ = 1.78*F*~(2,36)~ = 0.45      \**p* \< 0.0001*p* = 0.1906*p* = 0.6425
  ([Fig. 4*B*](#F4){ref-type="fig"})     Tukey HSD       Veh *Shank3^+/+^*vs Veh *Shank3^+/+^*vs Veh *Shank3^+/G^* vsVeh *Shank3^+/+^*vsVeh *Shank3^+/+^*vsVeh *Shank3^+/+^*vsTam *Shank3^+/+^*vsTam *Shank3^+/+^*vsTam *Shank3^+/G^*vs   Veh *Shank3^+/G^* Veh *Shank3^G/G^* Veh *Shank3^G/G^* Tam *Shank3^+/+^* Tam *Shank3^+/G^* Tam *Shank3^G/G^* Tam *Shank3^+/G^* Tam *Shank3^G/G^* Tam *Shank3^G/G^*                                                                *\*p* = 0.0447*\*p =* 0.0002*p* = 0.1242*p* = 1.0000*p* = 0.3864*\*p* = 0.0012*p* = 0.3864*\*p* = 0.0012*p* = 0.1548
  Two-weekTAM diet vs Veh diet (Cre+)    Two-way ANOVA   GenotypeTreatmentInteraction                                                                                                                                                                                                                                                                                                                         *F*~(2,36)~ = 18.64*F*~(1,36)~ = 4.92*F*~(2,36)~ = 1.49      \**p* \< 0.0001\**p* = 0.0329*p* = 0.2389
  ([Fig. 4*B*](#F4){ref-type="fig"})     Tukey HSD       Veh *Shank3^+/+^*vs Veh *Shank3^+/+^*vs Veh *Shank3^+/G^* vsVeh *Shank3^+/+^*vsVeh *Shank3^+/+^*vsVeh *Shank3^+/+^*vsTam *Shank3^+/+^*vsTam *Shank3^+/+^*vsTam *Shank3^+/G^*vs   Veh *Shank3^+/G^* Veh *Shank3^G/G^* Veh *Shank3^G/G^* Tam *Shank3^+/+^* Tam *Shank3^+/G^* Tam *Shank3^G/G^* Tam *Shank3^+/G^* Tam *Shank3^G/G^* Tam *Shank3^G/G^*                                                                *p* = 0.0523*\*p* = 0.0002*p* = 0.1395*p* = 1.0000*p* = 0.6185*\*p* = 0.0404*p* = 0.6185*\*p* = 0.0404*p* = 0.6526
  Four-weekTAM diet vs Veh diet (Cre+)   Two-way ANOVA   GenotypeTreatmentInteraction                                                                                                                                                                                                                                                                                                                         *F*~(2,36)~ = 13.70*F*~(1,36)~ = 5.73*F*~(2,36)~ = 1.55      \**p* \< 0.0001*\*p* = 0.0220*p* = 0.2262
  ([Fig. 4*B*](#F4){ref-type="fig"})     Tukey HSD       Veh *Shank3^+/+^*vs Veh *Shank3^+/+^*vs Veh *Shank3^+/G^* vsVeh *Shank3^+/+^*vsVeh *Shank3^+/+^*vsVeh *Shank3^+/+^*vsTam *Shank3^+/+^*vsTam *Shank3^+/+^*vsTam *Shank3^+/G^*vs   Veh *Shank3^+/G^* Veh *Shank3^G/G^* Veh *Shank3^G/G^* Tam *Shank3^+/+^* Tam *Shank3^+/G^* Tam *Shank3^G/G^* Tam *Shank3^+/G^* Tam *Shank3^G/G^* Tam *Shank3^G/G^*                                                                *p* = 0.1104*\*p* = 0.0004*p* = 1.0000*p* = 1.0000*p* = 0.9380*p* = 0.1530*p* = 0.9380*p* = 0.1530*p* = 0.6222
  Six-weekTAM diet vsVeh diet (Cre-)     Two-way ANOVA   GenotypeTreatmentInteraction                                                                                                                                                                                                                                                                                                                         *F*~(2,44)~ = 45.29*F*~(1,44)~ = 0.17*F*~(2,44)~ = 0.39      \**p* \< 0.0001*p* = 0.6783*p* = 0.7010
  ([Fig. 4*C*](#F4){ref-type="fig"})     Tukey HSD       Veh *Shank3^+/+^*vs Veh *Shank3^+/+^*vs Veh *Shank3^+/G^* vsVeh *Shank3^+/+^*vsVeh *Shank3^+/+^*vsVeh *Shank3^+/+^*vsTam *Shank3^+/+^*vsTam *Shank3^+/+^*vsTam *Shank3^+/G^*vs   Veh *Shank3^+/G^* Veh *Shank3^G/G^* Veh *Shank3^G/G^* Tam *Shank3^+/+^* Tam *Shank3^+/G^* Tam *Shank3^G/G^* Tam *Shank3^+/G^* Tam *Shank3^G/G^* Tam *Shank3^G/G^*                                                                *\*p* = 0.0008*\*p* = 0.0001*p* = 0.2915*p* = 0.9236*\*p* = 0.0007*\*p* = 0.0001*\*p* = 0.0046*\*p* = 0.0001*\*p* = 0.0255
                                                                                                                                                                                                                                                                                                                                                                                                                                                                           
  Six-weekTAM diet vsVeh diet (Cre+)     Two-way ANOVA   GenotypeTreatmentInteraction                                                                                                                                                                                                                                                                                                                         *F*~(2,112)~ = 7.81*F*~(1,112)~ = 14.67*F*~(2,112)~ = 4.87   \**p* \< 0.0001\**p* = 0.0002*\*p* = 0.0094
  ([Fig. 4*D*](#F4){ref-type="fig"})     Tukey HSD       Veh *Shank3^+/+^*vs Veh *Shank3^+/+^*vs Veh *Shank3^+/G^* vsVeh *Shank3^+/+^*vsVeh *Shank3^+/+^*vsVeh *Shank3^+/+^*vsTam *Shank3^+/+^*vsTam *Shank3^+/+^*vsTam *Shank3^+/G^*vs   Veh *Shank3^+/G^* Veh *Shank3^G/G^* Veh *Shank3^G/G^* Tam *Shank3^+/+^* Tam *Shank3^+/G^* Tam *Shank3^G/G^* Tam *Shank3^+/G^* Tam *Shank3^G/G^* Tam *Shank3^G/G^*                                                                *p* = 0.1319*\*p* = 0.0005\**p* = 0.0012*p* = 1.0000*p* = 0.7763*p* = 0.8507*p* = 0.6913*p* = 0.9308*p* = 0.2261

Significant at *P* \< 0.05 level.

###### 

Detailed statistical analysis of all behavior and electrophysiology performed in this study

  Vehicle-treated *Shank3^G^Cre^Tam^−*                                                                                        
  ------------------------------------------------- ------------------- --------------------------- ------------------------- ------------------------------------------------
  Nest width                                        Three-way rmANOVA   Genotype                    *F*~(2,58)~ = 4.07        [^\*^*p*](#TF1){ref-type="table-fn"} = 0.0222
  ([Fig. 5*A*](#F5){ref-type="fig"})                                    Time                        *F*~(2,116)~ = 19.12      [^\*^](#TF1){ref-type="table-fn"}*p* \< 0.0001
                                                                        Sex                         *F*~(1,58)~ = 0.26        *p* = 0.6119
                                                                        Genotype × time             *F*~(4,116)~ = 0.67       *p* = 0.6162
                                                    Tukey HSD           *Shank3^+/+^Cre^Tam^−* vs   *Shank3^+/G^Cre^Tam^−*    *p* = 0.5894
                                                                        *Shank3^+/+^Cre^Tam^−* vs   *Shank3^G/G^Cre^Tam^−*    [^\*^](#TF1){ref-type="table-fn"}*p* = 0.0089
                                                                        *Shank3^+/G^Cre^Tam^−* vs   *Shank3^G/G^Cre^Tam^−*    *p* = 0.1515
  Nest height                                       Three-way rmANOVA   Genotype                    *F*~(2,58)~ = 3.38        [^\*^](#TF1){ref-type="table-fn"}*p* = 0.0408
  ([Fig. 5*B*](#F5){ref-type="fig"})                                    Time                        *F*~(2,116)~ = 33.32      [^\*^](#TF1){ref-type="table-fn"}*p \<* 0.0001
                                                                        Sex                         *F*~(1,58)~ = 0.01        *p* = 0.9336
                                                                        Genotype × time             *F*~(4,116)~ = 0.46       *p* = 0.7621
                                                                        Genotype × sex              *F*~(2,58)~ = 1.82        *p* = 0.1710
                                                    Tukey HSD           *Shank3^+/+^Cre^Tam^−* vs   *Shank3^+/G^Cre^Tam^−*    *p* = 0.9865
                                                                        *Shank3^+/+^Cre^Tam^−* vs   *Shank3^G/G^Cre^Tam^−*    [^\*^](#TF1){ref-type="table-fn"}*p* = 0.0392
                                                                        *Shank3^+/G^Cre^Tam^− vs*   *Shank3^G/G^Cre^Tam^−*    [^\*^](#TF1){ref-type="table-fn"}*p* = 0.0473
  Marble burying                                    Two-way ANOVA       Genotype                    *F*~(2,58)~ = 12.30       [^\*^](#TF1){ref-type="table-fn"}*p* \< 0.0001
  ([Fig. 5*C*](#F5){ref-type="fig"})                                    Sex                         *F*~(1,58)~ = 0.13        *p* = 0.7208
                                                                        Genotype × time             *F*~(4,116)~ = 0.67       *p* = 0.6162
                                                    Tukey HSD           *Shank3^+/+^Cre^Tam^−* vs   *Shank3^+/G^Cre^Tam^−*    *p* = 0.4965
                                                                        *Shank3^+/+^Cre^Tam^−* vs   *Shank3^G/G^Cre^Tam^−*    [^\*^](#TF1){ref-type="table-fn"}*p* = 0.0001
                                                                        *Shank3^+/G^Cre^Tam^−* vs   *Shank3^G/G^Cre^Tam^−*    [^\*^](#TF1){ref-type="table-fn"}*p* = 0.0017
  Locomotor                                         Three-way rmANOVA   Genotype                    *F*~(2,58)~ = 0.47        *p* = 0.6274
  ([Fig. 5*D*](#F5){ref-type="fig"})                                    Time                        *F*~(23,1334)~ = 103.60   [^\*^](#TF1){ref-type="table-fn"}*p* \< 0.0001
                                                                        Sex                         *F*~(1,58)~ = 0.82        *p* = 0.3689
                                                                        Genotype × time             *F*~(46,1334)~ = 3.37     [^\*^*p*](#TF1){ref-type="table-fn"} \< 0.0001
                                                                        Genotype × sex              *F*~(2,58)~ = 0.37        *p* = 0.6893
                                                    Tukey HSD           *Shank3^+/+^Cre^Tam^−* vs   *Shank3^+/G^Cre^Tam^−*    *p* = 0.9828
                                                                        *Shank3^+/+^Cre^Tam^−* vs   *Shank3^G/G^Cre^Tam^−*    *p* = 0.5155
                                                                        *Shank3^+/G^Cre^Tam^−* vs   *Shank3^G/G^Cre^Tam^−*    *p* = 0.6796
  Rotarod                                           Three-way rmANOVA   Genotype                    *F*~(2,58)~ = 5.83        [^\*^*p*](#TF1){ref-type="table-fn"} = 0.0049
  ([Fig. 5*E*](#F5){ref-type="fig"})                                    Trial                       *F*~(7,406)~ = 13.89      [^\*^*p*](#TF1){ref-type="table-fn"} \< 0.0001
                                                                        Sex                         *F*~(1,58)~ = 4.31        [^\*^*p*](#TF1){ref-type="table-fn"} = 0.0424
                                                                        Genotype × trial            *F*~(14,406)~ = 1.87      [^\*^*p*](#TF1){ref-type="table-fn"} = 0.0282
                                                                        Genotype × sex              *F*~(2,58)~ = 0.94        *p* = 0.3970
                                                    Tukey HSD           *Shank3^+/+^Cre^Tam^−* vs   *Shank3^+/G^Cre^Tam^−*    *p* = 0.4183
                                                                        *Shank3^+/+^Cre^Tam^−* vs   *Shank3^G/G^Cre^Tam^−*    [^\*^](#TF1){ref-type="table-fn"}*p* = 0.0015
                                                                        *Shank3^+/G^Cre^Tam^−* vs   *Shank3^G/G^Cre^Tam^−*    *p* = 0.4183
  fEPSP slope                                       Two-way rmANOVA     Genotype                    *F*~(1,17)~ = 102.42      [^\*^*p*](#TF1){ref-type="table-fn"} \< 0.0001
  ([Fig. 5*F*](#F5){ref-type="fig"})                                    Intensity                   *F*~(7,119)~ = 36.51      [^\*^*p*](#TF1){ref-type="table-fn"} \< 0.0001
                                                                        Genotype × intensity        *F*~(7,119)~ = 2.90       [^\*^](#TF1){ref-type="table-fn"}*p* = 0.0078
  Fiber volley                                      Two-way rmANOVA     Genotype                    *F*~(1,8)~ = 5.12         *p* = 0.0535
                                                                        Intensity                   *F*~(7,56)~ = 69.13       [^\*^](#TF1){ref-type="table-fn"}*p* \< 0.0001
                                                                        Genotype × intensity        *F*~(7,56)~ = 3.51        [^\*^](#TF1){ref-type="table-fn"}*p* = 0.0034
  Tamoxifen-treated *Shank3^G^Cre^Tam^−*                                                                                      
  Nest width                                        Three-way rmANOVA   Genotype                    *F*~(2,54)~ = 5.09        [^\*^*p*](#TF1){ref-type="table-fn"} = 0.0047
  ([Fig. 6*A*](#F6){ref-type="fig"})                                    Time                        *F*~(2,108)~ = 23.28      [^\*^](#TF1){ref-type="table-fn"}*p* \< 0.0001
                                                                        Sex                         *F*~(1,54)~ = 0.31        *p* = 0.5813
                                                                        Genotype × time             *F*~(4,108)~ = 1.12       *p* = 0.3527
                                                                        Genotype × sex              *F*~(2,54)~ = 0.35        *p* = 0.7070
                                                    Tukey HSD           *Shank3^+/+^Cre^Tam^−* vs   *Shank3^+/G^Cre^Tam^−*    *p* = 0.3842
                                                                        *Shank3^+/+^Cre^Tam^−* vs   *Shank3^G/G^Cre^Tam^−*    [^\*^](#TF1){ref-type="table-fn"}*p* = 0.0068
                                                                        *Shank3^+/G^Cre^Tam^−* vs   *Shank3^G/G^Cre^Tam^−*    *p* = 0.1757
  Nest height                                       Three-way rmANOVA   Genotype                    *F*~(2,54)~ = 2.47        *p* = 0.0942
  ([Fig. 6*B*](#F6){ref-type="fig"})                                    Time                        *F*~(2,108)~ = 39.18      [^\*^](#TF1){ref-type="table-fn"}*p \<* 0.0001
                                                                        Sex                         *F*~(1,54)~ = 0.01        *p* = 0.9046
                                                                        Genotype × time             *F*~(4,108)~ = 1.07       *p* = 0.3753
                                                                        Genotype × sex              *F*~(2,54)~ = 0.14        *p* = 0.8719
                                                    Tukey HSD           *Shank3^+/+^Cre^Tam^−* vs   *Shank3^+/G^Cre^Tam^−*    *p* = 0.4260
                                                                        *Shank3^+/+^Cre^Tam^−* vs   *Shank3^G/G^Cre^Tam^−*    *p* = 0.0811
                                                                        *Shank3^+/G^Cre^Tam^−* vs   *Shank3^G/G^Cre^Tam^−*    *p* = 0.6415
                                                                                                                              
  Marble burying                                    Two-way ANOVA       Genotype                    *F*~(2,54)~ = 22.52       [^\*^](#TF1){ref-type="table-fn"}*p* \< 0.0001
  ([Fig. 6*C*](#F6){ref-type="fig"})                                    Sex                         *F*~(1,54)~ = 0.86        *p* = 0.3575
                                                                        Genotype × sex              *F*~(2,54)~ = 0.20        *p* = 0.8195
                                                    Tukey HSD           *Shank3^+/+^Cre^Tam^−* vs   *Shank3^+/G^Cre^Tam^−*    *p* = 0.0776
                                                                        *Shank3^+/+^Cre^Tam^−* vs   *Shank3^G/G^Cre^Tam^−*    [^\*^](#TF1){ref-type="table-fn"}*p* = 0.0001
                                                                        *Shank3^+/G^Cre^Tam^−* vs   *Shank3^G/G^Cre^Tam^−*    [^\*^](#TF1){ref-type="table-fn"}*p* = 0.0003
  Locomotor                                         Three-way rmANOVA   Genotype                    *F*~(2,54)~ = 5.20        [^\*^](#TF1){ref-type="table-fn"}*p* = 0.0086
  ([Fig. 6*D*](#F6){ref-type="fig"})                                    Time                        *F*~(23,1242)~ = 96.67    [^\*^](#TF1){ref-type="table-fn"}*p* \< 0.0001
                                                                        Sex                         *F*~(1,54)~ = 0.56        *p* = 0.4570
                                                                        Genotype × time             *F*~(46,1242)~ = 4.55     [^\*^*p*](#TF1){ref-type="table-fn"} \< 0.0001
                                                                        Genotype × sex              *F*~(2,54)~ = 0.11        *p* = 0.8928
                                                    Tukey HSD           *Shank3^+/+^Cre^Tam^−* vs   *Shank3^+/G^Cre^Tam^−*    *p* = 0.0740
                                                                        *Shank3^+/+^Cre^Tam^−* vs   *Shank3^G/G^Cre^Tam^−*    [^\*^](#TF1){ref-type="table-fn"}*p* = 0.0097
                                                                        *Shank3^+/G^Cre^Tam^−* vs   *Shank3^G/G^Cre^Tam^−*    *p* = 0.6566
  Rotarod                                           Three-way rmANOVA   Genotype                    *F*~(2,54)~ = 13.62       [^\*^*p*](#TF1){ref-type="table-fn"} \< 0.0001
  ([Fig. 6*E*](#F6){ref-type="fig"})                                    Trial                       *F*~(7,378)~ = 16.98      [^\*^*p*](#TF1){ref-type="table-fn"} \< 0.0001
                                                                        Sex                         *F*~(1,54)~ = 17.21       [^\*^*p*](#TF1){ref-type="table-fn"} = 0.0001
                                                                        Genotype × trial            *F*~(14,378)~ = 2.79      [^\*^*p*](#TF1){ref-type="table-fn"} = 0.0006
                                                                        Genotype × sex              *F*~(2,54)~ = 2.50        *p* = 0.0912
                                                    Tukey HSD           *Shank3^+/+^Cre^Tam^−* vs   *Shank3^+/G^Cre^Tam^−*    [^\*^](#TF1){ref-type="table-fn"}*p* = 0.0253
                                                                        *Shank3^+/+^Cre^Tam^−* vs   *Shank3^G/G^Cre^Tam^−*    [^\*^](#TF1){ref-type="table-fn"}*p* = 0.0001
                                                                        *Shank3^+/G^Cre^Tam^−* vs   *Shank3^G/G^Cre^Tam^−*    [^\*^](#TF1){ref-type="table-fn"}*p* = 0.0346
  fEPSP slope                                       Two-way rmANOVA     Genotype                    *F*~(1,40)~ = 8.33        [^\*^*p*](#TF1){ref-type="table-fn"} = 0.0063
  ([Fig. 6*F*](#F6){ref-type="fig"})                                    Intensity                   *F*~(7,280)~ = 113.08     [^\*^*p*](#TF1){ref-type="table-fn"} \< 0.0001
                                                                        Genotype × intensity        *F*~(7,280)~ = 9.94       [^\*^*p*](#TF1){ref-type="table-fn"} \< 0.0001
  Fiber volley                                      Two-way rmANOVA     Genotype                    *F*~(1,19)~ = 0.49        *p* = 0.4931
                                                                        Intensity                   *F*~(7,133)~ = 51.55      [^\*^](#TF1){ref-type="table-fn"}*p* \< 0.0001
                                                                        Genotype × intensity        *F*~(7,133)~ = 0.69       *p* = 0.6768
  Tamoxifen-treated *Shank3^G^Cre^Tam^+* mice                                                                                 
  Nest width                                        Three-way rmANOVA   Genotype                    *F*~(2,50)~ = 0.30        *p* = 0.7405
  ([Fig. 7*A*](#F7){ref-type="fig"})                                    Time                        *F*~(2,100)~ = 28.50      [^\*^](#TF1){ref-type="table-fn"}*p* \< 0.0001
                                                                        Sex                         *F*~(1,50)~ = 0.62        *p* = 0.4336
                                                                        Genotype × time             *F*~(4,100)~ = 1.12       *p* = 0.3531
                                                                        Genotype × sex              *F*~(2,50)~ = 0.22        *p* = 0.8038
                                                    Tukey HSD           *Shank3^+/+^Cre^Tam^+* vs   *Shank3^+/G^Cre^Tam^+*    *p* = 0.9947
                                                                        *Shank3^+/+^Cre^Tam^+* vs   *Shank3^G/G^Cre^Tam^+*    *p* = 0.7240
                                                                        *Shank3^+/G^Cre^Tam^+* vs   *Shank3^G/G^Cre^Tam^+*    *p* = 0.8221
  Nest height                                       Three-way rmANOVA   Genotype                    *F*~(2,50)~ = 0.07        *p* = 0.9335
  ([Fig. 7*B*](#F7){ref-type="fig"})                                    Time                        *F*~(2,100)~ = 35.62      [^\*^](#TF1){ref-type="table-fn"}*p* \< 0.0001
                                                                        Sex                         *F*~(1,50)~ = 0.58        *p* = 0.4490
                                                                        Genotype × time             *F*~(4,100)~ = 0.48       *p* = 0.7507
                                                                        Genotype × sex              *F*~(2,50)~ = 0.17        *p* = 0.8425
                                                    Tukey HSD           *Shank3^+/+^Cre^Tam^+* vs   *Shank3^+/G^Cre^Tam^+*    *p* = 0.9623
                                                                        *Shank3^+/+^Cre^Tam^+* vs   *Shank3^G/G^Cre^Tam^+*    *p* = 0.9767
                                                                        *Shank3^+/G^Cre^Tam^+* vs   *Shank3^G/G^Cre^Tam^+*    *p* = 0.9000
  Marble burying                                    Two-way ANOVA       Genotype                    *F*~(2,48)~ = 3.68        [^\*^](#TF1){ref-type="table-fn"}*p* = 0.0326
  ([Fig. 7*C*](#F7){ref-type="fig"})                                    Sex                         *F*~(1,48)~ = 0.00        *p* = 0.9634
                                                                        Genotype × sex              *F*~(2,48)~ = 0.26        *p* = 0.7688
                                                    Tukey HSD           *Shank3^+/+^Cre^Tam^+* vs   *Shank3^+/G^Cre^Tam^+*    *p* = 0.6972
                                                                        *Shank3^+/+^Cre^Tam^+* vs   *Shank3^G/G^Cre^Tam^+*    [^\*^](#TF1){ref-type="table-fn"}*p* = 0.0296
                                                                        *Shank3^+/G^Cre^Tam^+* vs   *Shank3^G/G^Cre^Tam^+*    *p* = 0.6972
  Locomotor                                         Three-way rmANOVA   Genotype                    *F*~(2,50)~ = 2.12        *p* = 0.1311
  ([Fig. 7*D*](#F7){ref-type="fig"})                                    Time                        *F*~(23,1150)~ = 99.68    [^\*^](#TF1){ref-type="table-fn"}*p* \< 0.0001
                                                                        Sex                         *F*~(1.50)~ = 0.49        *p* = 0.4866
                                                                        Genotype × time             *F*~(46,1150)~ = 1.82     [^\*^*p*](#TF1){ref-type="table-fn"} \< 0.0008
                                                                        Genotype × sex              *F*~(2,50)~ = 0.03        *p* = 0.9701
                                                    Tukey HSD           *Shank3^+/+^Cre^Tam^+* vs   *Shank3^+/G^Cre^Tam^+*    *p* = 0.8310
                                                                        *Shank3^+/+^Cre^Tam^+* vs   *Shank3^G/G^Cre^Tam^+*    *p* = 0.1097
                                                                        *Shank3^+/G^Cre^Tam^+* vs   *Shank3^G/G^Cre^Tam^+*    *p* = 0.4023
                                                                                                                              
  Rotarod                                           Three-way rmANOVA   Genotype                    *F*~(2,56)~ = 0.12        *p* = 0.8894
  ([Fig. 7*E*](#F7){ref-type="fig"})                                    Trial                       *F*~(7,392)~ = 17.89      [^\*^*p*](#TF1){ref-type="table-fn"} \< 0.0001
                                                                        Sex                         *F*~(1,56)~ = 4.46        [^\*^*p*](#TF1){ref-type="table-fn"} = 0.0392
                                                                        Genotype × trial            *F*~(14,392)~ = 0.76      *p* = 0.7082
                                                                        Genotype × sex              *F*~(2,56)~ = 0.29        *p* = 0.7499
                                                    Tukey HSD           *Shank3^+/+^Cre^Tam^+* vs   *Shank3^+/G^Cre^Tam^+*    *p* = 0.9642
                                                                        *Shank3^+/+^Cre^Tam^+* vs   *Shank3^G/G^Cre^Tam^+*    *p* = 0.9906
                                                                        *Shank3^+/G^Cre^Tam^+* vs   *Shank3^G/G^Cre^Tam^+*    *p* = 0.9351
  fEPSP slope                                       Two-way rmANOVA     Genotype                    *F*~(1,26)~ = 0.34        *p* = 0.5634
  ([Fig. 7*F*](#F7){ref-type="fig"})                                    Intensity                   *F*~(7,182)~ = 29.71      [^\*^*p*](#TF1){ref-type="table-fn"} \< 0.0001
                                                                        Genotype × intensity        *F*~(7,182)~ = 6.30       [^\*^*p*](#TF1){ref-type="table-fn"} \< 0.0001
  Fiber volley                                      Two-way rmANOVA     Genotype                    *F*~(1,11)~ = 0.46        *p* = 0.5135
                                                                        Intensity                   *F*~(7,77)~ = 24.06       [^\*^*p*](#TF1){ref-type="table-fn"} \< 0.0001
                                                                        Genotype × intensity        *F*~(7,77)~ = 0.16        *p* = 0.9915
  Vehicle-treated *Shank3^G^Cre^Tam^+* mice                                                                                   
  Nest width                                        Three-way rmANOVA   Genotype                    *F*~(2,56)~ = 2.33        *p* = 0.1065
  ([Fig. 8*A*](#F8){ref-type="fig"})                                    Time                        *F*~(2,112)~ = 34.73      [^\*^](#TF1){ref-type="table-fn"}*p* \< 0.0001
                                                                        Sex                         *F*~(1,56)~ = 0.44        *p* = 0.5100
                                                                        Genotype × time             *F*~(4,112)~ = 0.91       *p* = 0.4630
                                                                        Genotype × sex              *F*~(2,56)~ = 2.13        *p* = 0.1287
                                                    Tukey HSD           *Shank3^+/+^Cre^Tam^+* vs   *Shank3^+/G^Cre^Tam^+*    *p* = 0.6704
                                                                        *Shank3^+/+^Cre^Tam^+* vs   *Shank3^G/G^Cre^Tam^+*    *p* = 0.0637
                                                                        *Shank3^+/G^Cre^Tam^+* vs   *Shank3^G/G^Cre^Tam^+*    *p* = 0.3149
  Nest height                                       Three-way rmANOVA   Genotype                    *F*~(2,56)~ = 2.72        *p* = 0.0749
  ([Fig. 8*B*](#F8){ref-type="fig"})                                    Time                        *F*~(2,112)~ = 72.06      [^\*^](#TF1){ref-type="table-fn"}*p* \< 0.0001
                                                                        Sex                         *F*~(1,56)~ = 0.59        [^\*^](#TF1){ref-type="table-fn"}*p* = 0.0446
                                                                        Genotype × time             *F*~(4,112)~ = 1.32       *p* = 0.2687
                                                                        Genotype × sex              *F*~(2,56)~ = 0.82        *p* = 0.4466
                                                    Tukey HSD           *Shank3^+/+^Cre^Tam^+* vs   *Shank3^+/G^Cre^Tam^+*    *p* = 0.6704
                                                                        *Shank3^+/+^Cre^Tam^+* vs   *Shank3^G/G^Cre^Tam^+*    *p* = 0.0637
                                                                        *Shank3^+/G^Cre^Tam^+* vs   *Shank3^G/G^Cre^Tam^+*    *p* = 0.3149
  Marble burying                                    Two-way ANOVA       Genotype                    *F*~(2,55)~ = 15.78       [^\*^](#TF1){ref-type="table-fn"}*p* \< 0.0001
  ([Fig. 8*C*](#F8){ref-type="fig"})                                    Sex                         *F*~(1,55)~ = 0.50        *p* = 0.4810
                                                                        Genotype × sex              *F*~(2,55)~ = 0.12        *p* = 0.8874
                                                    Tukey HSD           *Shank3^+/+^Cre^Tam^+* vs   *Shank3^+/G^Cre^Tam^+*    [^\*^](#TF1){ref-type="table-fn"}*p* = 0.0005
                                                                        *Shank3^+/+^Cre^Tam^+* vs   *Shank3^G/G^Cre^Tam^+*    [^\*^](#TF1){ref-type="table-fn"}*p* = 0.0001
                                                                        *Shank3^+/G^Cre^Tam^+* vs   *Shank3^G/G^Cre^Tam^+*    *p* = 0.3265
  Locomotor                                         Three-way rmANOVA   Genotype                    *F*~(2,56)~ = 2.48        *p* = 0.0926
  ([Fig. 8*D*](#F8){ref-type="fig"})                                    Time                        *F*~(23,1288)~ = 101.49   [^\*^](#TF1){ref-type="table-fn"}*p* \< 0.0001
                                                                        Sex                         *F*~(1,56)~ = 1.98        *p* = 0.1644
                                                                        Genotype × time             *F*~(46,1288)~ = 2.57     [^\*^*p*](#TF1){ref-type="table-fn"} \< 0.0001
                                                                        Genotype × sex              *F*~(2,56)~ = 0.11        *p* = 0.8946
                                                    Tukey HSD           *Shank3^+/+^Cre^Tam^+* vs   *Shank3^+/G^Cre^Tam^+*    *p* = 0.0842
                                                                        *Shank3^+/+^Cre^Tam^+* vs   *Shank3^G/G^Cre^Tam^+*    *p* = 0.9893
                                                                        *Shank3^+/G^Cre^Tam^+* vs   *Shank3^G/G^Cre^Tam^+*    *p* = 0.1944
  Rotarod                                           Three-way rmANOVA   Genotype                    *F*~(1,56)~ = 0.12        *p* = 0.8894
  ([Fig. 8*E*](#F8){ref-type="fig"})                                    Trial                       *F*~(7,392)~ = 17.89      [^\*^*p*](#TF1){ref-type="table-fn"} \< 0.0001
                                                                        Sex                         *F*~(1,56)~ = 4.46        [^\*^*p*](#TF1){ref-type="table-fn"} = 0.0392
                                                                        Genotype × trial            *F*~(14,392)~ = 0.76      *p* = 0.7082
                                                                        Genotype × sex              *F*~(2,56)~ = 0.29        *p* = 0.7499
                                                    Tukey HSD           *Shank3^+/+^Cre^Tam^+* vs   *Shank3^+/G^Cre^Tam^+*    *p* = 0.9642
                                                                        *Shank3^+/+^Cre^Tam^+* vs   *Shank3^G/G^Cre^Tam^+*    *p* = 0.9906
                                                                        *Shank3^+/G^Cre^Tam^+* vs   *Shank3^G/G^Cre^Tam^+*    *p* = 0.9351
  fEPSP slope                                       Two-way rmANOVA     Genotype                    *F*~(1,30)~ = 0.26        *p* = 0.6130
  ([Fig. 8*F*](#F8){ref-type="fig"})                                    Intensity                   *F*~(7,210)~ = 52.49      [^\*^*p*](#TF1){ref-type="table-fn"} \< 0.0001
                                                                        Genotype × intensity        *F*~(7,210)~ = 0.45       *p* = 0.8699
  Fiber volley                                      Two-way rmANOVA     Genotype                    *F*~(1,15)~ = 1.80        *p* = 0.1995
                                                                        Intensity                   *F*~(7,105)~ = 155.78     [^\*^](#TF1){ref-type="table-fn"}*p* \< 0.0001
                                                                        Genotype × intensity        *F*~(7,105)~ = 2.96       [^\*^](#TF1){ref-type="table-fn"}*p* = 0.0072
                                                                                                                              
  Effect of CAG-Cre^Tam^ on *Shank3^+/+^* mice                                                                                
  Nest height                                       Three-way rmANOVA   CAG-Cre^Tam^                *F*~(1,49)~ = 3.12        *p* = 0.0837
                                                                        Time                        *F*~(2,98)~ = 44.08       [^\*^](#TF1){ref-type="table-fn"}*p \<* 0.0001
                                                                        Sex                         *F*~(1,49)~ = 3.83        *p* = 0.0559
                                                                        CAG-Cre^Tam^ × time         *F*~(2,98)~ = 1.65        *p* = 0.1972
                                                                        CAG-Cre^Tam^ × sex          *F*~(2,549~ = 0.19        *p* = 0.6674
  Nest width                                        Three-way rmANOVA   CAG-Cre^Tam^                *F*~(1,49)~ = 0.08        *p* = 0.7752
                                                                        Time                        *F*~(2,98)~ = 27.22       [^\*^](#TF1){ref-type="table-fn"}*p* \< 0.0001
                                                                        Sex                         *F*~(1,49)~ = 3.37        *p* = 0.0725
                                                                        CAG-Cre^Tam^ × time         *F*~(2,98)~ = 1.28        *p* = 0.2839
                                                                        CAG-Cre^Tam^ × sex          *F*~(2,49)~ = 0.299       *p* = 0.5872
  Marble                                            Two-way ANOVA       CAG-Cre^Tam^                *F*~(1,49)~ = 0.34        [^\*^](#TF1){ref-type="table-fn"}*p =* 0.5654
  Burying                                                               Sex                         *F*~(1,49)~ = 2.93        *p* = 0.0934
                                                                        CAG-Cre^Tam^ × sex          *F*~(1,49)~ = 0.43        *p* = 0.5127
  Locomotor                                         Three-way rmANOVA   Genotype                    *F*~(1,49)~ = 16.00       [^\*^](#TF1){ref-type="table-fn"}*p* = 0.0002
                                                                        Time                        *F*~(23,1127)~ = 110.93   [^\*^](#TF1){ref-type="table-fn"}*p* \< 0.0001
                                                                        Sex                         *F*~(1,49)~ = 2.38        *p* = 0.1293
                                                                        CAG-Cre^Tam^ × time         *F*~(23,1127)~ = 1.46     *p* = 0.0749
                                                                        CAG-Cre^Tam^ × sex          *F*~(1,49)~ = 0.19        *p* = 0.6626
  Rotarod                                           Three-way rmANOVA   CAG-Cre^Tam^                *F*~(1,49)~ = 0.21        *p* = 0.6472
                                                                        Trial                       *F*~(7,343)~ = 19.90      [^\*^*p*](#TF1){ref-type="table-fn"} \< 0.0001
                                                                        Sex                         *F*~(1,49)~ = 1.99        *p* = 0.1651
                                                                        CAG-Cre^Tam^ × trial        *F*~(7,343)~ = 0.76       *p* = 0.6180
                                                                        CAG-Cre^Tam^ × sex          *F*~(1,49)~ = 0.79        *p* = 0.5973
  fEPSP slope                                       Two-way rmANOVA     CAG-Cre^Tam^                *F*~(1,24)~ = 86.39       [^\*^*p*](#TF1){ref-type="table-fn"} \< 0.0001
  ([Fig. 9*A*](#F9){ref-type="fig"})                                    Intensity                   *F*~(7,168)~ = 58.00      [^\*^*p*](#TF1){ref-type="table-fn"} \< 0.0001
                                                                        CAG-Cre^Tam^ × intensity    *F*~(7,168)~ = 3.60       [^\*^*p*](#TF1){ref-type="table-fn"} = 0.0012
  Fiber volley                                      Two-way rmANOVA     CAG-Cre^Tam^                *F*~(1,9)~ = 0.69         *p* = 0.4270
                                                                        Intensity                   *F*~(7,63)~ = 56.18       [^\*^](#TF1){ref-type="table-fn"}*p* \< 0.0001
                                                                        CAG-Cre^Tam^ × intensity    *F*~(7,63)~ = 2.95        [^\*^*p*](#TF1){ref-type="table-fn"} = 0.0098
  Effect of CAG-Cre^Tam^ on *Shank3^G/^* ^G^ mice                                                                             
  Nest height                                       Three-way rmANOVA   CAG-Cre^Tam^                *F*~(1,30)~ = 0.33        *p* = 0.5693
                                                                        Time                        *F*~(2,60)~ = 21.20       [^\*^](#TF1){ref-type="table-fn"}*p \<* 0.0001
                                                                        Sex                         *F*~(1,30)~ = 1.94        *p* = 0.1736
                                                                        CAG-Cre^Tam^ × time         *F*~(2,60)~ = 0.38        *p* = 0.6865
                                                                        CAG-Cre^Tam^ × sex          *F*~(2,60)~ = 0.44        *p* = 0.5132
  Nest width                                        Three-way rmANOVA   CAG-Cre^Tam^                *F*~(1,30)~ = 0.12        *p* = 0.7331
                                                                        Time                        *F*~(2,60)~ = 20.06       [^\*^](#TF1){ref-type="table-fn"}*p* \< 0.0001
                                                                        Sex                         *F*~(1,30)~ = 3.37        *p* = 0.0762
                                                                        CAG-Cre^Tam^ × time         *F*~(2,60)~ = 0.08        *p* = 0.9219
                                                                        CAG-Cre^Tam^ × sex          *F*~(2,60)~ = 0.02        *p* = 0.8884
  Marble                                            Two-way ANOVA       CAG-Cre^Tam^                *F*~(1,30)~ = 0.00        *p =* 0.9828
  Burying                                                               Sex                         *F*~(1,30)~ = 0.40        *p* = 0.5294
                                                                        CAG-Cre^Tam^ × sex          *F*~(1,30)~ = 1.03        *p* = 0.3179
  Locomotor                                         Three-way rmANOVA   CAG-Cre^Tam^                *F*~(1,30)~ = 11.83       [^\*^](#TF1){ref-type="table-fn"}*p* = 0.0017
                                                                        Time                        *F*~(23,690)~ = 36.91     [^\*^](#TF1){ref-type="table-fn"}*p* \< 0.0001
                                                                        Sex                         *F*~(1,30)~ = 0.05        *p* = 0.8193
                                                                        CAG-Cre^Tam^ × time         *F*~(23,690)~ = 0.89      *p* = 0.6145
                                                                        CAG-Cre^Tam^ × sex          *F*~(1,30)~ = 0.18        *p* = 0.6777
  Rotarod                                           Three-way rmANOVA   CAG-Cre^Tam^                *F*~(1,30)~ = 5.99        [^\*^*p*](#TF1){ref-type="table-fn"} = 0.0205
                                                                        Trial                       *F*~(7,210)~ = 4.39       [^\*^*p*](#TF1){ref-type="table-fn"} \< 0.0001
                                                                        Sex                         *F*~(1,30)~ = 1.99        *p* = 0.1682
                                                                        CAG-Cre^Tam^ × trial        *F*~(7,210)~ = 1.00       *p* = 0.4323
                                                                        CAG-Cre^Tam^ × sex          *F*~(1,30)~ = 1.42        *p* = 0.2422
  fEPSP slope                                       Two-way rmANOVA     CAG-Cre^Tam^                *F*~(1,23)~ = 0.58        *p* = 0.4527
  ([Fig. 9*B*](#F9){ref-type="fig"})                                    Intensity                   *F*~(7,161)~ = 33.71      [^\*^*p*](#TF1){ref-type="table-fn"} \< 0.0001
                                                                        CAG-Cre^Tam^ × intensity    *F*~(7,161)~ = 0.173      *p* = 0.9904
  Fiber volley                                                          CAG-Cre^Tam^                *F*~(1,8)~ = 0.20         *p* = 0.6695
                                                                        Intensity                   *F*~(7,56)~ = 28.25       [^\*^](#TF1){ref-type="table-fn"}*p* \< 0.0001
                                                                        CAG-Cre^Tam^ × intensity    *F*~(7,56)~ = 2.67        [^\*^](#TF1){ref-type="table-fn"}*p* = 0.0184

Significant at 0.05 level.

Results {#s4}
=======

Treatment of *Shank3^G^Cre^Tam^+* mice with tamoxifen diet results in rescued expression of SHANK3 protein in whole-brain lysates {#s4A}
---------------------------------------------------------------------------------------------------------------------------------

In tamoxifen-treated, cre-positive, heterozygous and homozygous mice, the level of SHANK3 protein was rescued effectively to WT levels ([Fig. 4*C*,*D*](#F4){ref-type="fig"}). Statistics for [Figure 4](#F4){ref-type="fig"} are summarized in [Table 1](#T1){ref-type="table"}. Adult (eight-week-old) mice were assigned to either the tamoxifen treatment group, that received tamoxifen diet for six weeks, or the control group, that continued to receive vehicle diet. After the six-week treatment period, both groups received vehicle diet for at least a two-week wash-out period before testing. This tamoxifen treatment protocol resulted in nearly complete biochemical rescue of SHANK3 expression with no significant difference in SHANK3 protein expression levels among tamoxifen-treated, mutant *Shank3^G/G^Cre^Tam^+* mice (adult-induced genetic reversal) compared to each of the several WT groups (vehicle-treated *Shank3^+/+^Cre^Tam^+*, tamoxifen-treated *Shank3^+/+^Cre^Tam^+*, vehicle-treated *Shank3^+/+^Cre^Tam^−*, and tamoxifen-treated *Shank3^+/+^Cre^Tam^−*). Similarly, no significant difference was observed among tamoxifen-treated heterozygous *Shank3^+/G^Cre^Tam^+* mice and all other WT groups. Consistent with our expectations and previous findings ([@B25]), all other heterozygous (vehicle-treated *Shank3^+/G^Cre^Tam^+*, vehicle-treated *Shank3^+/G^Cre^Tam^−*, and tamoxifen-treated *Shank3^+/G^Cre^Tam^−*) and homozygous (vehicle-treated *Shank3^G/G^Cre^Tam^+*, vehicle-treated *Shank3^G/G^Cre^Tam^−*, and tamoxifen-treated *Shank3^G/G^ Cre^Tam^−*) groups without genetic reversal demonstrated an ∼50% reduction (heterozygotes) or nearly complete loss (homozygotes) of SHANK3 protein expression. Importantly, tamoxifen diet had no effect on SHANK3 protein expression levels in cre-negative mice (*Shank3^+/G^Cre^Tam^−* and *Shank3^G/G^Cre^Tam^−*; [Fig. 4*C*)](#F4){ref-type="fig"}.

Replication of behavioral and synaptic phenotypes in vehicle-treated *Shank3^G^Cre^Tam^−* mice {#s4B}
----------------------------------------------------------------------------------------------

*Shank3^G^* mice ([@B25]), as well as Shank3^ΔC^ mice ([@B17]), show what we refer to as an altered response to novelty phenotype that we have now replicated in our vehicle-treated, cre-negative, *Shank3^G/G^Cre^Tam^−* mice. We tested *Shank3^+/+^Cre^Tam^−*, *Shank3^+/G^Cre^Tam^−,* and *Shank3^G/G^Cre^Tam^−* mice in a nest-building task. Homozygous *Shank3^G/G^Cre^Tam^−* mutant mice showed decreased nest width ([Fig. 5*A*](#F5){ref-type="fig"}) and height ([Fig. 5*B*](#F5){ref-type="fig"}) over a 90-min period compared to WT *Shank3^+/+^Cre^Tam^−* controls. We also replicated our previously demonstrated phenotype ([@B25]) in a marble burying task with *Shank3^G/G^Cre^Tam^−* mice showing a significant decrease in the number of marbles buried compared to WT controls ([Fig. 5*C*)](#F5){ref-type="fig"}. Complete statistical analysis for these and all subsequent experiments is detailed in [Table 2](#T2){ref-type="table"}.

![Vehicle-treated *Shank3^G/G^Cre^Tam^−* mice exhibit clear behavioral and physiologic phenotypes. *Shank3^G/G^Cre^Tam^−* mice exhibit a novelty avoidance phenotype by building smaller nests in both nest width (***A***) and height (***B***) over a 90-min period, burying fewer marbles over a 30-min period (***C***), and exhibiting hypoactivity within the first 5 min of the open field test (***D***) compared to *Shank3^+/+^Cre^Tam^−* controls. ***E***, Rotarod testing demonstrates that motor learning and coordination are decreased in *Shank3^G/G^Cre^Tam^−* mice compared to controls. *Shank3^+/+^ n* = 27, *Shank3^+/G^ n* = 18, *Shank3^G/G^ n* = 19. ***F***, Synaptic transmission in the hippocampus is impaired in *Shank3^G/G^Cre^Tam^−* mice with decreased fEPSP in response to stimulus intensity compared to *Shank3^+/+^Cre^Tam^−* mice. Inset, Average of five consecutive raw traces at stimulus intensities 0--350 μA in 50-μA steps from *Shank3^+/+^*(top) and *Shank3^G/G^* (bottom) mice; scale bar = 0.5 mV, 5 ms. *Shank3^+/+^ n* = 10 slices from five mice, *Shank3^G/G^ n* = 9 slices from three mice; \**p* \< 0.05, \*\**p* \< 0.01, \*\*\**p* \< 0.001, \*\*\*\**p* \< 0.0001.](enu9991930480005){#F5}

In accordance with the altered response to novelty phenotype, *Shank3^G/G^Cre^Tam^−* mice also demonstrated significantly decreased initial locomotor activity in a novel environment ([Fig. 5*D*)](#F5){ref-type="fig"}. As we previously demonstrated with both *Shank3^G/G^* ([@B25]) and *Shank3^ΔC^* ([@B17]) mice, there is no main effect of genotype on the total number of beam breaks. Tukey *post hoc* analysis, however, revealed that *Shank3^G/G^Cre^Tam^−* mice are hypoactive during the first 5 min in the novel environment compared to *Shank3^+/G^Cre^Tam^−* and *Shank3^+/+^Cre^Tam^−* littermates ([Fig. 5*D*)](#F5){ref-type="fig"}.

We next examined motor coordination and learning on the accelerating rotarod in *Shank3^G^Cre^Tam^−* mice. A decreased motor coordination phenotype was previously observed in these and related *Shank3* mutant mice ([@B25]; [@B17]). *Shank3^G/G^Cre^Tam^−* mice exhibited a significant decrease in coordination on the rotarod, as well as a decrease in motor learning, indicated by an overall main effect of genotype and an interaction between genotype and trial ([Fig. 5*E*)](#F5){ref-type="fig"}. We also identified a main effect of sex that revealed longer latencies to fall in female mice than in males. No interaction between genotype and sex was observed, but overall, females performed better than males.

Finally, we investigated basal synaptic transmission in the hippocampus using extracellular electrophysiology in acute brain slices from male, vehicle-treated WT *Shank3^+/+^Cre^Tam^−* and homozygous *Shank3^G/G^Cre^Tam^−* mice. We found a significant decrease in *Shank3^G/G^Cre^Tam^−* synaptic transmission compared to that of *Shank3^+/+^Cre^Tam^−* mice, with a significant decrease in the I/O relationship of stimulus intensity to the slope of the fEPSP ([Fig. 5*F*](#F5){ref-type="fig"}) at CA3 Schaffer-collateral to area CA1 synapses. Main effects of both genotype and stimulus intensity are observed along with a significant interaction between genotype and stimulus intensity. Overall, *Shank3^G/G^Cre^Tam^−* mice exhibited decreased basal synaptic strength compared to controls at stimulus intensities \>50 μA and reached a 44% weaker maximum fEPSP slope. Fiber volley amplitude was not affected. Thus, breeding with the *Cre^Tam^* transgenic mouse line did not alter the previously observed phenotypes in *Shank3^G/G^* mice ([@B25]).

Replication of behavioral and synaptic phenotypes in tamoxifen-treated, *Shank3^G/G^Cre^Tam^*− mice {#s4C}
---------------------------------------------------------------------------------------------------

As expected, tamoxifen treatment did not rescue behavioral phenotypes in Cre-negative, mutant *Shank3^G/G^Cre^Tam^−* mice compared to tamoxifen-treated, WT, Cre-negative *Shank3^+/+^Cre^Tam^−* control mice. Nest width was significantly decreased in tamoxifen-treated *Shank3^G/G^Cre^Tam^−* mice compared to controls, with a main effect of genotype present in nest width ([Fig. 6*A*)](#F6){ref-type="fig"}. The decrease in nest height of *Shank3^G/G^Cre^Tam^−* mice, however, did not reach statistical significance ([Fig. 6*B*)](#F6){ref-type="fig"}. Similarly, in the marble burying task, tamoxifen-treated *Shank3^G/G^Cre^Tam^−* mice buried fewer marbles over a 30-min period than did tamoxifen-treated *Shank3^+/+^Cre^Tam^−* controls ([Fig. 6*C*)](#F6){ref-type="fig"}.

![Behavioral and synaptic phenotypes in *Shank3^G/G^Cre^Tam^−* mice are not rescued by treatment with six weeks of tamoxifen diet. Nesting behavior is not rescued by tamoxifen treatment in *Shank3^G/G^Cre^Tam^−* mice with regard to nest width (***A***), although there is no main effect of genotype with regard to nest height (***B***). Marble burying (***C***) remains impaired in tamoxifen-treated *Shank3^G/G^Cre^Tam^−* mice with decreased number of marbles buried compared to controls. Locomotor activity also remains decreased in tamoxifen-treated *Shank3^G/G^Cre^Tam^−* mice at the start of the open field test (***D***). Latency to fall off the rotarod (***E***) remains decreased in tamoxifen-treated *Shank3^G/G^Cre^Tam^−* mice compared to controls. *Shank3^+/+^ n* = 25, *Shank3^+/G^ n* = 19, *Shank3^G/G^ n* = 16. ***F***, Tamoxifen treatment does not rescue synaptic transmission in *Shank3^G/G^Cre^Tam^−* mice. Inset, Average of five consecutive traces at each stimulus intensity 0--350 μA in 50-μA steps from *Shank3^+/+^* (top) and *Shank3^G/G^* (bottom) mice treated with six weeks of tamoxifen diet; scale bar = 0.25 mV, 5 ms. *Shank3^+/+^ n* = 22 slices from eight mice, *Shank3^G/G^ n* = 20 slices from six mice; \**p* \< 0.05, \*\**p* \< 0.01, \*\*\**p* \< 0.001, \*\*\*\**p* \< 0.0001.](enu9991930480006){#F6}

The same lack of effect of tamoxifen on behavioral phenotypes in *Shank3^G/G^Cre^Tam^−* mice was observed in locomotor, motor learning, and motor coordination tasks. In locomotor activity ([Fig. 6*D*](#F6){ref-type="fig"}), there was a main effect of genotype due to a decrease in the number of beam breaks by tamoxifen-treated *Shank3^G/G^Cre^Tam^−* mice compared to *Shank3^+/G^Cre^Tam^−* and *Shank3^+/+^Cre^Tam^−* mice over the 120-min testing period. As with vehicle-treated mice without the *Cre^Tam^* transgene ([Fig. 5*D*](#F5){ref-type="fig"}), Tukey *post hoc* analysis showed that this effect was primarily due to hypoactivity of *Shank3^G/G^Cre^Tam^−* mice in the first 5 min of testing. We also observed a main effect of genotype with both *Shank3^+/G^Cre^Tam^−* and *Shank3^G/G^Cre^Tam^−* mice demonstrating decreased coordination compared to WT *Shank3^+/+^Cre^Tam^−* controls ([Fig. 6*E*)](#F6){ref-type="fig"}.

Tamoxifen treatment also had no effect on the reduction in synaptic transmission in cre-negative *Shank3^G/G^Cre^Tam^−* mice compared to WT. Synaptic strength in response to increasing stimulus intensity ([Fig. 6*F*](#F6){ref-type="fig"}) remained significantly decreased in tamoxifen-treated *Shank3^G/G^Cre^Tam^−* mice compared to WT *Shank3^+/+^Cre^Tam^−* controls, particularly at higher stimulus intensities. Fiber volley amplitude was similar between *Shank3^+/+^Cre^Tam^−* and *Shank3^G/G^Cre^Tam^−* mice, suggesting no effect on presynaptic excitability or axon number. As predicted, these behavioral and synaptic data demonstrated that tamoxifen treatment in the absence of the *Cre^Tam^* transgene did not rescue deficits in irreversible *Shank3^G/G^Cre^Tam^−* mice.

Apparent partial genetic rescue of behavioral and physiologic phenotypes in tamoxifen-treated, reversible *Shank3^G/G^Cre^Tam^+* mice {#s4D}
-------------------------------------------------------------------------------------------------------------------------------------

*Shank3^G^Cre^Tam^+* mice treated with six weeks of tamoxifen diet exhibited partial rescue of novelty avoidance phenotypes identified in *Shank3^G^Cre^Tam^−* mice. In the nest-building test, there was no longer a main effect of genotype on nest width ([Fig. 7*A*](#F7){ref-type="fig"}) or height ([Fig. 7*B*](#F7){ref-type="fig"}) over a 30-min period. However, in the marble-burying task ([Fig. 7*C*](#F7){ref-type="fig"}), tamoxifen treatment did not rescue the main effect of genotype on number of marbles buried. *Shank3^G/G^Cre^Tam^+* mice buried 57% fewer marbles than WT *Shank3^+/+^Cre^Tam^+* mice also treated with tamoxifen diet. Tamoxifen treatment also failed to rescue the hypoactive locomotor response to a novel environment seen in vehicle-treated ([Fig. 5*D*](#F5){ref-type="fig"}) and tamoxifen-treated ([Fig. 6*D*](#F6){ref-type="fig"}) *Shank3^G^Cre^Tam^−* mice. In the first 5 min of the open field test ([Fig. 7*D*](#F7){ref-type="fig"}), Tukey *post hoc* analysis identified a significant 31% decrease in locomotor activity in *Shank3^G/G^Cre^Tam^+* mice compared to WT *Shank3^+/+^Cre^Tam^+* controls.

![Incomplete genetic rescue of behavioral and physiologic phenotypes in tamoxifen-treated *Shank3^G/G^Cre^Tam^+* mice. There is no main effect of genotype on nest width (***A***) or height (***B***) in tamoxifen-treated *Shank3^G/G^Cre^Tam^+* mice, suggesting successful rescue of the *Shank3^G/G^* nest-building phenotype. ***C***, The *Shank3^G/G^* marble-burying phenotype is not rescued in tamoxifen-treated *Shank3^G/G^Cre^Tam^+* mice, nor is the initial hypoactivity observed in the open field test (***D***). Tamoxifen treatment of *Shank3^G/G^Cre^Tam^+* mice does successfully eliminate the main effects of genotype in the time to fall from the rotarod. *Shank3^+/+^ n* = 23, *Shank3^+/G^ n* = 15, *Shank3^G/G^ n* = 18 (***E***). ***F***, There is no main effect of genotype on fEPSP slope over a range of stimulus intensities in tamoxifen-treated *Shank3^+/+^Cre^Tam^+* and *Shank3^G/G^Cre^Tam^+* mice. Inset, Average of five consecutive traces at each stimulus intensity 0--350 μA in 50-μA steps from *Shank3^+/+^* (top) and *Shank3^G/G^* (bottom) mice treated with six weeks of tamoxifen diet; scale bar = 0.25 mV, 5 ms. *Shank3^+/+^ n* = 16 slices from eight mice, *Shank3^G/G^ n* = 12 slices from six mice; \**p* \< 0.05, \*\*\**p* \< 0.0001, \*\*\*\**p* \< 0.00001.](enu9991930480007){#F7}

Testing on the rotarod ([Fig. 7*E*](#F7){ref-type="fig"}) revealed that motor learning or coordination was also rescued; no significant effect of genotype was apparent with tamoxifen treatment of *Shank3^G/G^Cre^Tam^+* mice. That said, a trend toward decreased motor coordination/learning was still evident in this experiment. After tamoxifen treatment, there was no main effect of genotype, but significant effects of trial and sex were apparent, with females again outperforming males and with no interaction between genotype and sex.

Synaptic transmission was apparently rescued in *Shank3^G/G^Cre^Tam^+* mice treated with tamoxifen diet for six weeks. fEPSP slope in response to increasing stimulus intensity ([Fig. 7*F*](#F7){ref-type="fig"}) and maximum fEPSP slope (*Shank3^+/+^*: 0.49 ± 0.07 mV, *Shank3^G/G^*: 0.56 ± 0.09 mV) were comparable between tamoxifen-treated *Shank3^G/G^Cre^Tam^+* mice and tamoxifen-treated WT *Shank3^+/+^Cre^Tam^+* controls, as were fiber volley amplitudes.

Vehicle-treated *Shank3^G/G^Cre^Tam^+* controls demonstrate that apparent partial genetic reversal with tamoxifen is uninterpretable {#s4E}
------------------------------------------------------------------------------------------------------------------------------------

We performed critical controls throughout this study to account for potential off-target effects of the *Shank3^G^* gene and of tamoxifen treatment on autism-associated behaviors and synaptic transmission. Control experiments resulted in robust replication of the original behavioral and synaptic deficits following both vehicle ([Fig. 5](#F5){ref-type="fig"}) and tamoxifen ([Fig. 6](#F6){ref-type="fig"}) treatment on the same genetic background in cre-negative *Shank3^G^Cre^Tam^−* mice.

Thus, one is tempted to conclude that genetic reversal of SHANK3 expression in adult mice leads to reversal of both synaptic dysfunction and at least one behavioral difference in *Shank3^G/G^* mice ([Fig. 7](#F7){ref-type="fig"}). Such a conclusion would have potential ramifications for development of future treatments and for timing of such interventions in future clinical trials. As a final, critical control, we also examined vehicle-treated, *Shank3^G/G^Cre^Tam^*+ mice with the expectation that they too would replicate previously published ([@B17]; [@B25]) and currently replicated ([Figs. 5](#F5){ref-type="fig"}, [6](#F6){ref-type="fig"}), behavioral and synaptic phenotypes. This was not the case.

Surprisingly, vehicle-treated, mutant *Shank3^G/G^Cre^Tam^+* mice showed no difference in nest width ([Fig. 8*A*](#F8){ref-type="fig"}) or height ([Fig. 8*B*](#F8){ref-type="fig"}) compared to vehicle-treated, WT *Shank3^+/+^Cre^Tam^*+ controls (a behavior that appeared to have been rescued by tamoxifen treatment in [Fig. 7*A*,*B*](#F7){ref-type="fig"}). Marble burying ([Fig. 8*C*](#F8){ref-type="fig"}) and initial locomotor activity ([Fig. 8*D*](#F8){ref-type="fig"}) were significantly impaired in vehicle-treated *Shank3^G/G^Cre^Tam^+* mice, as expected, replicating the robust *Shank3^G^*phenotypes identified in the original *Shank3^G^* and *Shank3^G^Cre^Tam^−*lines (and the lack of rescue with tamoxifen treatment in [Fig. 7*C*,*D*](#F7){ref-type="fig"}). However, motor coordination and learning on the rotarod ([Fig. 8*E*](#F8){ref-type="fig"}) were not significantly different between vehicle-treated *Shank3^G/G^Cre^Tam^*+ and *Shank3^+/+^Cre^Tam^+* mice. Perhaps more surprisingly, synaptic transmission ([Fig. 8*F*](#F8){ref-type="fig"}) was not significantly different between vehicle-treated, mutant *Shank3^G/G^Cre^Tam^*+ and WT *Shank3^+/+^Cre^Tam^+* mice. The lack of significant difference in the vehicle-treated *Shank3^G/G^Cre^Tam^+* mice from controls in nest-building, motor learning/coordination, and synaptic transmission makes it difficult to conclude that the apparent reversal in tamoxifen-treated *Shank3^G/G^Cre^Tam^*+ mice in nest building and synaptic transmission is due to rescue of SHANK3 protein expression.

![Unexpected, partial genetic "rescue" of behavioral and synaptic phenotypes in vehicle-treated *Shank3^G/G^Cre^Tam^+* mice. The decreases in nest width (***A***) and height (***B***) in *Shank3^G/G^* mice are rescued in vehicle-treated *Shank3^G/G^Cre^Tam^+* mice. The *Shank3^G/G^*marble-burying phenotype (***C***) and initial locomotor hypoactivity in the open field test (***D***) are not rescued in vehicle-treated *Shank3^G/G^Cre^Tam^+* mice. ***E***, There is no main effect of genotype in time to fall from the rotarod in vehicle-treated *Shank3^G^Cre^Tam^+* mice. *Shank3^+/+^ n* = 26, *Shank3^+/G^ n* = 21, *Shank3^G/G^ n* = 15. ***F***, There is no main effect of genotype on fEPSP slope in response to a range of stimulus intensities. Inset, Average of five consecutive traces at each stimulus intensity 0--350 μA in 50-μA steps from *Shank3^+/+^* (top) and *Shank3^G/G^* (bottom) mice treated with vehicle diet; scale bar = 0.25 mV, 5 ms. *Shank3^+/+^ n* = 16 slices from six mice, *Shank3^G/G^ n* = 16 slices from five mice; \**p* \< 0.05, \*\*\**p* \< 0.0001, \*\*\*\**p* \< 0.00001.](enu9991930480008){#F8}

One possible remaining explanation for the lack of a synaptic phenotype in our Cre-positive mice treated with either vehicle ([Fig. 8](#F8){ref-type="fig"}) or tamoxifen ([Fig. 7](#F7){ref-type="fig"}) could be that the Cre transgene affects synaptic transmission in WT mice. Indeed, additional comparisons and analysis of our electrophysiological data indicated an effect of the *Cre^Tam^* transgene on WT *Shank3^+/+^* synaptic transmission ([Fig. 9*A*](#F9){ref-type="fig"}), with *Cre^Tam^*+ WT mice having markedly reduced I/O curves compared to *Cre^Tam^−* WT mice ([Fig. 9*A*)](#F9){ref-type="fig"}. This was in contrast to a lack of effect of *Cre^Tam^* on mutant *Shank3^G/G^* synaptic transmission ([Fig. 9*B*)](#F9){ref-type="fig"}. The presence of the *Cre^Tam^* gene had no effect on the amplitude of the fiber volley in either *Shank3^+/+^*or *Shank3^G/G^* mice, suggesting this effect is not due to a decrease in axon number or presynaptic excitability.

![Effect of the *Cre^Tam^* transgene on synaptic physiology in WT *Shank3^+/+^* and mutant *Shank3^G/G^* mice. The *Cre^Tam^* transgene causes a dramatic decrease in the relationship between stimulus intensity and fEPSP slope (***A***) in WT *Shank3^+/+^* mice. Inset, Average of five consecutive raw traces at each stimulus intensity from 0 to 350 μA in 50-μA steps from *Shank3^+/+^Cre^Tam^−* mice (top) and *Shank3^+/+^Cre^Tam^+* mice (bottom); scale bar = 0.25 mV, 5 ms. *Shank3^+/+^Cre^Tam^− n* = 10 slices from four mice, *Shank3^+/+^Cre^Tam^+ n* = 16 slices from six mice. ***B***, The relationship between stimulus intensity and fEPSP slope in mutant *Shank3^G/G^* mice is unchanged with *Cre^Tam^* transgene expression. Inset, Average of five consecutive raw traces at each stimulus intensity from 0 to 350 μA in 50-μA steps from *Shank3^G/G^Cre^Tam^−* mice (top) and *Shank3^G/G^Cre^Tam^+* mice (bottom); scale bar =0.25 mV, 5 ms. *Shank3^G/G^Cre^Tam^− n* = 9 slices from three mice, *Shank3^G/G^Cre^Tam^+ n* = 16 slices from five mice; \**p* \< 0.05, \*\**p* \< 0.01, \*\*\**p* \< 0.001, \*\*\*\**p* \< 0.0001.](enu9991930480009){#F9}

Discussion {#s5}
==========

Conditional gene targeting can allow for regulated spatial or temporal control of gene expression ([@B12]) and has been successfully harnessed in mouse models of autism ([@B11]; [@B6]; [@B24]; [@B19]). In the ideal experiment, nuclear localization of Cre-recombinase on tamoxifen administration restores WT gene expression and rescues neuronal function and behavior. These studies can also offer insights into the critical windows in development for successful rescue ([@B6]; [@B24]; [@B19]). The potential clinical impact of adult genetic reversal is even greater, offering an avenue for permanent restoration of normal function even after brain development is complete ([@B27]).

We sought to apply adult genetic rescue to our robust *Shank3^G^* Exon 21 mouse model of autism ([@B25]) by crossing the original *Shank3^G^* mouse line with another that expresses tamoxifen-inducible Cre recombinase under the CMV-chicken actin promotor, CAGGCre-ER ([@B12]), abbreviated here as Cre^Tam^. This Cre^Tam^ mouse results in widespread, tamoxifen-inducible, Cre-recombinase activation. The Cre^Tam^ mouse line used in this study is well-described in the literature and has been used to rescue phenotypes in other mouse models of autism and neuropsychiatric disorders ([@B11]; [@B6]; [@B24]; [@B19]).

Our study had two objectives. First, we validated our *Shank3^G^Cre^Tam^* mouse line in *Cre^Tam^−* mice by replicating the synaptic and behavioral phenotypes identified in the original *Shank3^G^* mouse ([@B25]), and in our earlier *Shank3^ΔC^* mouse ([@B17]). As expected, Shank3^G/G^Cre^Tam^− mice exhibited a novelty avoidance phenotype, hypoactivity in response to a novel environment, motor coordination deficits, and decreased hippocampal synaptic transmission compared to *Shank3^+/+^Cre^Tam^−* controls, faithfully replicating the strongest phenotypes observed in the original *Shank3^G^* ([@B25]) and *Shank3^ΔC^* ([@B17]) mouse lines. This was true of both tamoxifen and vehicle-treated *Cre^Tam^−* cohorts. We chose not to examine anxiety-like behaviors or other behavioral tasks that we previously demonstrated were not affected in this mutant mouse model.

The second objective of our study was adult-induced reversal of those phenotypes in tamoxifen-treated *Shank3^G^Cre^Tam^+* mice. We achieved complete rescue of WT SHANK3 expression in adult, tamoxifen-treated *Shank3^G^Cre^Tam^+* mice using our six-week tamoxifen treatment, similar to our previous report ([@B25]). Synaptic transmission deficits also appeared to be rescued with tamoxifen treatment in *Shank3^G^Cre^Tam^+* mice, suggesting that synaptic function could be restored in adult animals. Our behavioral data were less promising with rescue of both nesting behavior and rotarod performance, but not marble burying or initial hypoactivity in the locomotor activity test.

When taken at face value before further examination of *Cre^Tam^*+, vehicle-treated controls, our data suggest conditional rescue of some *Shank3^G^* phenotypes following adult, conditional, genetic reversal. For completeness, we included a key additional control. We analyzed behavior and synaptic transmission in *Cre^Tam^+* mice treated with vehicle. We expected this to yield the same phenotypes as the original Shank3*^G^* and *Shank3^G/G^Cre^Tam^−* mice. This was true for marble burying and initial hypoactivity in a novel environment, but we still observed apparent rescue of nesting behavior, rotarod performance, and synaptic transmission even in the absence of tamoxifen. On closer inspection, we noticed that synaptic transmission in *Cre+* WT animals was reduced to *Shank3^G/G^* levels in the presence of the transgene. Thus, we are unable to conclude that adult, genetic reversal of our *Shank3* exon 21 insertion mutants is effective. Furthermore, our data suggest that *Cre^Tam^* may be having an effect on synaptic transmission and behavior, thus giving the appearance of rescue.

While we were performing our experiments, a publication from Dr. Guoping Feng's laboratory demonstrated genetic reversal of WT SHANK3 expression, striatal physiology, and some behaviors by crossing the same *Cre^Tam^* mouse line with a different *Shank3* mutant model targeting exons 13--16 (*Shank3^PDZ^*). Tamoxifen treatment of the *Shank3^PDZ^*mutant led to rescued expression of most major protein isoforms of SHANK3 when compared to vehicle-treated *Shank3^PDZ^* mutants ([@B19]). They initially replicated behavioral and synaptic deficits in their floxed *Shank3^PDZ^* mutants without first crossing them to *Cre^Tam^*. Furthermore, this study compared *WTCre^Tam^+* and *Shank3^PDZ^Cre^Tam^+* mice treated with tamoxifen to one another, using vehicle-treated *Shank3^PDZ^Cre^Tam^+* mice as an additional comparison group ([@B19]). They did not perform a comparison between vehicle-treated *WTCre^Tam^*+ and *Shank3^PDZ^Cre^Tam^*+ mice to rule out effects of the *Cre^Tam^* transgene independent of tamoxifen treatment ([@B19]). Our data suggest that such a comparison may lead to apparent rescue of a subset of behavioral and synaptic phenotypes, at least on the *Shank3^G/G^* mutant background. They did, however, see additional, broader rescue of behaviors with tamoxifen treatment earlier in life, suggesting that these additionally rescued behaviors earlier in development were not likely due to spurious effects of *Cre^Tam^*alone in their experiments.

There are, of course, other important differences in methodology between the [@B19] study and ours. First, our mouse model targets exon 21 of the *Shank3* gene and results in loss of all three major isoforms of SHANK3 ([@B25]) whereas the Mei et al., study targets exons 13--16 which disrupts the PDZ domain and results in loss of different isoforms of SHANK3 ([@B23]; [@B19]). Tamoxifen treatment procedures also differed between studies. We administered tamoxifen in chow fed to adult mice for six weeks, while [@B19] used an oral gavage protocol at 5--8 mg/d depending on mouse weight. Neither study observed tamoxifen toxicity in adult mice, but [@B19] did report tamoxifen toxicity in three-week-old mice. Both groups adhered to a two-week washout period before testing.

Our adult genetic rescue experiments included a complete set of controls for a total of 12 groups tested, including controls for the *Shank3^G^* allele (heterozygous and homozygous), the *Cre^Tam^* transgene, and tamoxifen treatment. [@B19] tested three groups in their adult genetic reversal experiments: *Shank3^+/+^Cre^Tam^+* treated with tamoxifen, homozygous *Shank3^PDZ^Cre^Tam^+* with vehicle, and homozygous *Shank3^PDZ^Cre^Tam^+* with tamoxifen, with no reported controls for tamoxifen effects or for *Cre^Tam^* transgene effects in WT mice. Furthermore, in the [@B19] study, the homozygous mutant mice were bred separately from a cross of heterozygotes crossed with homozygotes to generate *Cre^Tam^+* homozygous mice for treatment with vehicle or tamoxifen. The *Shank3^+/+^Cre^Tam^+* mice and homozygous *Shank3^PDZ/PDZ^Cre^Tam^+* mice used in their experiments were generated from completely separate crosses of *Shank3^+/+^Cre^Tam^+/−* mice with *Shank3^+/+^Cre^Tam^+/−* mice (to yield the *Shank3^+/+^Cre^Tam^*± WT controls) and *Shank3^PDZ/PDZ^Cre^Tam^+/−* with *Shank3^PDZ/PDZ^Cre^Tam^+/−* (to yield the *Shank3^PDZ/PDZ^Cre^Tam^*± homozygous mutant mice; [@B19]). This means that the *Shank3^+/+^*comparators were generated from a completely separate cross with different parental genotypes than the *Shank3^PDZ/PDZ^Cre^Tam^+* mutants. In our study, all mice were generated from a single parental cross of *Shank3^+/G^Cre^Tam^−* mutants with *Shank3^+/G^Cre^Tam^+*. This allowed for each group tested to have its own internal *Shank3^+/+^* control from the same parents, same *Cre^Tam^+* status, and same treatment status within a littermate pair or triplet. These efforts may decrease the likelihood of misinterpretation of our adult genetic rescue experiments in this study.

Overall, we can conclude that *Shank3^G^* genetic reversal results in complete reversal of SHANK3 protein expression in the brain, a result that we have demonstrated here and in our previous publication ([@B25]). We cannot conclude, however, that this biochemical rescue leads to rescue of any behavioral or synaptic phenotypes in our mutants. In fact, it appears that the *Cre^Tam^* transgene has complex effects on WT mouse synaptic transmission in WT *Shank3* ^+/+^ mice. We can also conclude that we have successfully replicated our previous behavioral and electrophysiologic findings in two previous, similar *Shank3* mutant mouse models ([@B17]; [@B25]). We offer this study as an important cautionary tale demonstrating that any attempt at genetic reversal must be accompanied by all appropriate controls, including careful control of parental genotypes, simultaneous *Cre^Tam^* controls, and comparisons among all vehicle and tamoxifen-treated groups for accurate interpretation of results. We cannot interpret our findings in a manner that negates previously published findings using *Cre^Tam^*in other genetic models or backgrounds. We can only stipulate that our genetic reversal data are not able to be interpreted as clearly successful genetic reversal.

Acknowledgments: C.M.P. has accepted travel funds and honoraria to speak once at each of the following companies: Psychogenics, Inc.; Astra-Zeneca; Roche; Pfizer; and Dainippon Sumitomo Pharma Co. C.M.P. also has investigator-initiated grant funding for clinical research with Novartis.

Synthesis {#s6}
=========

Reviewing Editor: Alfonso Represa, INSERM

Decisions are customarily a result of the Reviewing Editor and the peer reviewers coming together and discussing their recommendations until a consensus is reached. When revisions are invited, a fact-based synthesis statement explaining their decision and outlining what is needed to prepare a revision will be listed below. The following reviewer(s) agreed to reveal their identity: NONE.

Dear authors,

Your manuscript has been evaluated by two reviewers that strongly appreciated the quality of the work and the interest of the results. They propose a few changes that I\'m synthesizing below and that I recommend to take into account for acceptance:

-It would be important to add some details about housing conditions of the mice (e.g., day/night rhythm, mixed- or homogenous-genotype groups, size of the housing groups).

\- Please keep the same scales for the equivalent graphs in the figures 5, 6, 7, and 8 as well as within Figure 9, to ease comparisons between the different groups of mice.

\- check please for grammar, particularly in the abstract. There are some typos throughout the text that should be corrected.

\- Although you have shown recombination using western blot, we think that a Southern blot would further validate their western blot-recombination results.

\- In Figure 4B, you can show Tam 1 week after vehicle followed by Tam 2 and 4 weeks for a better understanding of the graph.

\- We noticed that unlike in other graphs, the \* is not indicated in Fig 5,6,7 A&B . Please correct this.

\- Was there any change in the fibre volley vs stimulus intensity checked in Fig 5, 6, 7? If so, please include it in the manuscript.

Referees were also suggesting some additional experiments that would help providing more information on the mechanisms at the synaptic level, but after discussion we concluded that performing them will require more than two months and that they were no necessary for reaching the main conclusion. However, I\'m including them below for information. It might be that you have additional data on this respect that can be included in the final manuscript.

\- Could the authors check for any change in anxiety level by doing the elevated plus maze and whether it is rescued.

-Did the authors investigate whether LTP as well as synaptic transmission was rescued?

-Could the authors show whether any change in AMPA/NMDA after the rescue as the synaptic transmission is restored?

\- Could the authors show whether any signaling proteins downstream of NMDARs are restored?

Author Response {#s7}
===============

Dear Dr. Represa,

We thank the reviewers and editors for their helpful comments on our manuscript, "Apparent Genetic Rescue of Adult Shank3 Exon 21 Insertion Mutation Mice Tempered by Appropriate Control Experiments". Please see the attached manuscript with our revisions marked by red text as well as our response to reviewer suggestions below.

-It would be important to add some details about housing conditions of the mice (e.g., day/night rhythm, mixed- or homogenous-genotype groups, size of the housing groups).

Mice were housed in a reversed, 12 hr light/dark cycle and housed in mixed genotype groups of 2-4 per cage. Details were added to the Methods section as follows:

Page 3 Lines 123-128:

"Same-sex littermates with mixed Shank3 and CreTam genotypes were housed together 2-4 per cage following weaning between postnatal days P21-P28. Mice were kept on a 12:12 light:dark cycle with experiments performed during the light cycle (6:00 AM \-- 6:00 PM). Mice receiving tamoxifen treatment were housed on in the same room, but on a separate rack from mice in the control condition."

\- Please keep the same scales for the equivalent graphs in the figures 5, 6, 7, and 8 as well as within Figure 9, to ease comparisons between the different groups of mice.

We have revised these graphs as requested.

Figures 5-9:

Revised to share the same axes for comparable experiments and identical layouts.

\- check please for grammar, particularly in the abstract. There are some typos throughout the text that should be corrected.

We performed a thorough check by two native English speakers and by Word spell and Grammar checks. Tenses were revised to favor past tense whenever possible to keep tense as consistent as possible throughout. If there are specific issues with grammar that are systematic, we are very open to having these pointed out. We are very happy to edit further if needed.

\- Although you have shown recombination using western blot, we think that a Southern blot would further validate their western blot-recombination results.

We have added Figure 4E depicting an example Southern blot of creTam+, WT and homozygous mutant brain tissue treated with vehicle or tamoxifen. This panel is reproduced below for the reviewers\' convenience.

Figure 4 (E) Example Southern blot of brain tissue in CreTam+, WT and Shank3G/G homozygous mutant mice treated with Vehicle or Tamoxifen (TAM, Rev=band expected following cre-mediated recombination of floxed mutant, Mut=band expected for floxed mutant before cre recombination, WT=band expected in WT mice without mutant allele).

\- In Figure 4B, you can show Tam 1 week after vehicle followed by Tam 2 and 4 weeks for a better understanding of the graph.

The figure has been revised as requested.

Figure 4B

Reordered as vehicle, 1 week, 2 week, and 4 week TAM diet. The long, continuous blot inset above the original figure 4B was divided up by treatment group to correspond to the new order of treatment groups represented in the summary graph below.

\- We noticed that unlike in other graphs, the \* is not indicated in Fig 5,6,7 A&B. Please correct this.

Asterix "\*" were added wherever individual points were statistically significant in post-hoc tests. Otherwise, main effects are noted in each figure consistently.

\- Was there any change in the fibre volley vs stimulus intensity checked in Fig 5, 6, 7? If so, please include it in the manuscript.

We did not identify any changes in fibre volley amplitudes among groups that affect our conclusions. This has been reflected in the text as follows:

Page 12 Lines 356-357:

"Fiber volley amplitude was not affected."

Page 19 Lines 419-421:

"Fiber volley amplitude was similar between Shank3+/+CreTam− and Shank3G/GCreTam− mice suggesting no effect on presynaptic excitability or axon number."

Page 21 Lines 461-462:

"&, as are fiber volley amplitudes."

Page 25 Lines 527-529:

"The presence of the CreTam gene had no effect on the amplitude of the fiber volley in either Shank3+/+ or Shank3G/G mice, suggesting a synapse-specific mechanism rather than a decrease in axon number or presynaptic excitability."

All figures:

Saved as TIFF files at 300 DPI as stated in ENeuro\'s publication requirements.

We thank the reviewers for their time and consideration of our manuscript and look forward to your final decision.

Sincerely,

Craig M. Powell, M.D., Ph.D.
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